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Abstract 
 
Chemokines and chemokine receptors are key mediators of inflammation and important 
regulators of leukocyte migration in homeostatic conditions as well as during infection and 
cancer. The atypical receptor ACKR2 is a scavenger receptor for many inflammatory CC 
chemokines, it is expressed either by non-hematopoietic cells or by hematopoietic cells, 
and it has been shown to prevent the development of exacerbated inflammatory reactions.  
In an effort to understand the contribution of this receptor in the regulation of myeloid cell 
mobilization and myeloid cell effector functions, we investigated the role of ACKR2 in a 
murine model of myeloid cell mobilization, and in a model of experimental metastasis. 
The deficiency of ACKR2 was associated with increased mobilization of monocytes and 
neutrophils from the bone marrow (BM) and with increased number of monocytes 
confined to BM sinusoids compared to Wild-type (WT) mice. BM chimera experiments 
showed that the increased mobilization was due to the absence of ACKR2 in the 
hematopoietic compartment. The analysis of hematopoietic progenitor cells (HPCs) 
revealed that ACKR2 is expressed by Lin−Sca-1+c-Kit+ cells (LSK) to faint thereafter in 
more mature myeloid progenitor cells (MPCs) in contrast with the canonical chemokine 
receptor CCR2. Moreover, HPCs from Ackr2-/- mice expressed higher levels of CCR1, 
CCR2 and CCR5, but not of CXCR4 and they had higher differentiation rate compared to 
ACKR2 sufficient LSK. Although neutrophils express low levels of ACKR2 compared to 
LSK, we found that neutrophils from Ackr2 deficient mice, as well as their HPCs, 
expressed higher level of CC chemokine receptors and exhibited a more activated 
phenotype compared to WT. Furthermore, neutrophil depletion and neutrophil adoptive 
transfer experiments demonstrated that only Ackr2 deficient neutrophils were sufficient to 
control the metastatic seeding of B16 melanoma cells into the lung.  
To enhance the metastatic protection observed in Ackr2-/- mice, we treated WT and Ackr2-/- 
tumor bearing mice with AMD3100, the competitive inhibitor of CXCR4, which is known 
to induce a rapid neutrophil mobilization from the BM. However, AMD3100 treatment did 
not further improve the metastatic protection in Ackr2-/- mice, whereas decreased the 
number of metastases in WT mice. Finally, by using the human promyelocytic cell line 
HL-60, we demonstrated that ACKR2 directly exerted a negative regulation of CC 
chemokine receptor expression and cell differentiation. Indeed, HL-60, when transfected 
with a vector overexpressing ACKR2, had decreased transcript levels of CCR2 and 
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CD11b. These data suggest the ACKR2 is involved in the regulation of chemokine 
availability and leukocyte recruitment. Moreover, ACKR2 directly controls HPC 
differentiation, myeloid cell mobilization and their effector function through the inhibition 
of CC chemokine receptor expression. 
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Introduction 
 
 
1. The chemokine system 
 
Cell migration is essential for the activation and orientation of innate and adaptive 
immunity during the processes of immune surveillance, inflammation, and development [1, 
2]. Several cytokines and growth factors, such as macrophage-colony stimulating factors 
(M-CSF) and vascular endothelial factor (VEGF), regulate directional migration of 
leukocytes. The main mediators of leukocyte trafficking are chemokines, low molecular 
weight proteins (8-12 KDa) belonging to a family of small chemotactic cytokines secreted 
by cells.  The name “chemo-kines” derived from their ability to induce chemotaxis in 
responsive cells, which express dedicated chemokine receptors [3].  
Chemokine system is highly redundant and promiscuous: the same receptor can recognize 
more than one chemokine and multiple receptors can bind the same ligand [4]. To date, 
approximately 50 human chemokines and 20 receptors have been identified [5] (Figure 1).  
 
          
Figure 1: Chemokines and chemokine receptors. The same receptor can recognize more 
than one chemokine and multiple receptors can bind the same ligand. Only a minority of 
receptors has one ligand [6]. 
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1.1 Chemokine function 
 
Chemotactic cytokines were firstly identified for their role as potent chemo-attractant for 
leukocytes, such as monocytes and neutrophils, and were defined as important mediators 
of acute and chronic inflammation [2, 7].  
During inflammatory process, chemokines (e.g. CCL2, CCL3, and CXCL8) play a key role 
in promoting leukocyte recruitment to the site of inflammation. Chemokines secreted in 
response to primary pro-inflammatory factors, such as interleukin-1 (IL-1) and tumor 
necrosis factor (TNF)-α, bind to glycosaminoglycans (GAGs) on endothelial cell surface. 
This binding is crucial for retaining chemokines and increasing chemokine concentration 
on blood vessels at the inflammatory site, providing cues for chemokine receptors and 
leukocyte migration. Next, the interaction between selectins expressed on the endothelium 
and leukocytes causes leukocyte adhesion and rolling along the cell surface; finally, the 
binding of integrin lymphocyte function-associated antigen 1 (LFA-1) on leukocyte 
surface to the adhesion molecule-1 (ICAM-1) expressed on endothelial cells, promotes 
leukocyte arrest and extravasation [8, 9]. Despite their predominant chemotactic activity, 
in the last decade several studies have shown that chemokines also regulate the 
development, the homeostasis and the pathogenesis of many human diseases. For instance, 
they are involved in ontogenesis of vascular and nervous system; they regulate 
angiogenesis and fibrosis, and control the differentiation and proliferation of HPCs [10-
13]. 
 
 
1.2 Chemokine structure 
 
Chemokines are single polypeptide chain composed of 70-100 amino acid residues in 
length, with a molecular weight between 8-12 KDa. Chemokines have low amino acid 
sequence homology, but they all have four well-conserved cysteine residues, which form 
two disulphide bonds between the first and the third cysteine and between the second and 
the fourth cysteine. These bounds confer to chemokines a conserved tertiary structure. This 
structure consists of a disordered amino-terminus, three-stranded antiparallel β-sheet and a 
carboxy-terminal α-helix [14]. 
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1.3 Chemokine classification 
 
Chemokines are classified on the basis of structural properties and according to their 
production. Indeed, depending on the position of cysteine residues in their N-terminus, 
chemokines can be classified into 4 subfamilies: CC, CXC, XC and CX3C (Figure 2) [2, 
15]. The CC chemokines are the largest family of chemokines and have the first two of the 
four cysteine residues in adjacent position. CC chemokines mainly attract mononuclear 
cells, such as monocytes, natural killer (NK) cells, T and B lymphocytes. This family 
include: CCL2, also called monocyte chemoattractant protein 1 (MCP-1) that is a potent 
agonist for monocytes, dendritic cells (DCs), memory T cells, and basophils; CCL3, also 
called macrophage inflammatory protein (MIP)-1α; CCL4 (MIP-1β) and CCL5 
(RANTES) [16]. The second largest family of chemokines is represented by CXC 
chemokines, which have an amino acid between the first two cysteines; the CXC 
chemokines can be further classified in ERL- and ERL+ chemokines, based on the presence 
or absence of the ELR (Glu-Leu-Arg) motif [14]. ERL- chemokine, except CXCL12, are 
angiostatic factors that inhibit the formation of blood vessels, whereas ERL+ chemokine are 
angiogenic factors [12, 17]. Among CXC chemokines there are CXCL1 and CXCL2, 
which are important for polymorphonuclear leukocyte recruitment to the site of 
inflammation. CX3C family is composed by only one member: CX3CL1 (fractalkine), 
which has three amino acids separating the initial pair of cysteines in the N-terminus [18]. 
Finally, the XC subfamily is composed of chemokines with only two cysteines residues 
and only one N-terminal cysteine. XC chemokines include: XCL1 (lymphotactin-α) and 
XCL2 (lymphotactin- β) [19].  
On the basis of their function, chemokines can be also distinguished in homeostatic and 
inflammatory chemokines [20]. Homeostatic chemokines (e.g. CXCL12, CXCL13, 
CCL14, and CCL19) are constitutively produced and regulate basal leukocyte trafficking, 
such as lymphocyte homing to secondary lymphoid organs. Inflammatory chemokines (e.g. 
CCL2, CCL5, and CXCL8) are inducible molecules secreted during inflammatory 
response, upon infection or tissue injury, and they drive leukocyte recruitment to the site of 
inflammation. However, this classification is not strict; indeed some chemokines exert both 
inflammatory and homeostatic functions, depending on the context, and are therefore 
called dual-function chemokines. 
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Figure 2: Chemokine subfamilies. Chemokines are classified into 4 subfamilies: CC, 
CXC, C and CX3C depending on the position of cysteine residues in their N-terminus [21]. 
 
 
1.4 Chemokine receptors 
 
Chemokines exert their specific function through the interaction with chemokine receptors 
expressed on their target cells [7]. Depending on the type of chemokine they bind, 
chemokine receptors can be classified in CCR that bind CC chemokines, CXCR that bind 
CXC chemokines, CXCR1 that binds CX3CL1, and XCR that bind the two XC 
chemokines [22]. Moreover, according to the type of chemokine they bind, these receptors 
can be either inflammatory or homeostatic chemokine receptors. Chemokine receptors are 
7-transmembrane (7TM) receptors and they are coupled to hetero-trimeric GTP-binding 
proteins (G-protein) of the Gi type, sensitive to Bordetella pertussis toxin. These receptors 
are single polypeptide chain and have a high conserved structure characterized by an 
external N-terminus domain, seven transmembrane domains, three extracellular and three 
intracellular loops, and a serine/threonine-rich intracellular C-terminal domain. The N-
terminal domain is important for the specificity of ligand binding, whereas the C-terminal 
domain, together with other motifs in the transmembrane domains and intracellular loops, 
mediates the interaction with signaling molecules and is important for receptor 
internalization [14]. The interaction between chemokines and their receptors involves two 
important sites of chemokine structure, the docking and the triggering domains. The 
docking domain is the rigid loop that follows the second cysteine and is recognized by the 
N-terminus of the receptor [23, 24]. Ligand binding to the receptor through the docking 
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domain reduces chemokine mobility and facilitates receptor interaction with triggering 
domain, which is in proximity of the N-terminal domain and promotes receptor activation. 
Upon ligand engagement, the G-protein α subunit dissociates from the βγ subunits of 
heterotrimeric complex and βγ subunits rapidly activate signal events [25]. Conserved 
motifs in the structure of chemokine receptors are important for signaling and they include: 
an aspartic acid residue, a Thr-X-Pro (TXP; where X denotes any amino acid) motif in the 
second transmembrane domain, and an Arg–Tyr–Leu–Ala–Ile–Val (DRYLAIV) motif 
between the third transmembrane domain and the second intracellular loop [14]. 
Besides their apparent redundancy, chemokine receptors differ in their capacity to induce a 
diversity of signal transduction pathways including: mitogen-activated protein (MAP) 
kinases, phospholipase Cβ2, phopshoinositide 3-kinase (PI3K) and RAS pathway (Figure 
3) [25].  
 
                                     
 
Figure 3: Chemokine receptor signaling pathways. Scheme of the most effectors 
involved in the chemokine signal transduction [25]. 
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2. Chemokines and chemokine receptors in cancer-related 
inflammation 
 
Chemokines and their receptors are important mediators of cancer-related inflammation, 
which is a critical component of tumor initiation, promotion and progression. Accordingly, 
recent discoveries about their role had facilitated the development of novel therapies to 
improve cancer treatment [26].  
The link between cancer and inflammation can be schematically explained as consisting of 
an intrinsic or an extrinsic pathway [27]. The intrinsic pathway is represented by genetic 
alterations (e.g. oncogene) that cause tumor and induce the activation of inflammatory 
pathways. Different studies have demonstrated that chemokines and chemokine receptors 
are direct target of several oncogene activations. For example, oncogenic activation of 
RAS-RAF signaling pathway induces the activation of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and the production of inflammatory 
chemokines, such as CXCL8. Conversely, the extrinsic pathway is due to the establishment 
of inflammatory condition that increase the risk of cancer [27].  
Inflammatory cells, including macrophages, neutrophils, subset of T cells and DCs, are 
commonly found infiltrating tumors, where they can produce cytokines, chemokines and 
growth factors that directly or indirectly support cancer growth [28].  
On the other hand, effective anti-tumor immunity depends on inflammatory mediators that 
contribute to the activation of key immune cells such as DCs, for the induction of robust T 
cell response. In this view, CCL2 has been shown to promote the recruitment of pro-
inflammatory monocytes in the tumor site and to be able to directly sustain tumor growth 
and spread. On the other hand, high levels of CCL4, CCL5, CXCL9, CXCL10, and 
CXCL11, which induce the recruitment of activated T cells, have been associated with 
good prognosis in many human cancers [29]. 
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2.1  Sources of chemokines and chemokine receptors in tumors 
 
The vast majority of transcription factors activated in tumor cells regulates the production 
of many chemokines, cytokines and prostaglandins [27]. These factors recruit various 
leukocytes and activate the same transcription factors in inflammatory cells, stromal cells 
and cancer cells, thus promoting the production of more inflammatory mediators and the 
establishment of a tumor promoting microenvironment. For instance, CXCL8, which is 
one of the most abundant chemokine produced by human tumors and stromal cells, is over-
expressed in colon, lung, prostate, ovarian carcinoma and melanoma [30, 31], CXCL1 can 
be expressed by melanoma cells, CXCL5 by non-small cell lung cancer, CXCL6 by 
gastrointestinal tumors, CCL20 by pancreatic, renal and breast cancer, and papillary 
thyroid carcinoma, CCL5 can be produced by papillary thyroid carcinoma, CXCL12 by 
ovarian carcinoma and CCL19 by breast carcinoma [32-38]. In addition to produce 
chemokines, many cancer cells express a variety of chemokine receptors. CXCR4 is the 
receptor expressed by the majority of cancer cell types, including cancers of epithelial, 
mesenchymal and haematopoeitic origin [11]. For example, it is expressed by ovarian 
carcinomas, neuroblastoma, glioblastoma and tumor cells from breast, prostate, pancreatic 
and lung [39-45]; CXCR4 can be co-expressed with other CC or CXC chemokine 
receptors, indeed it has been found to be co-expressed with CCR7 in human breast cancer 
cells and melanoma cells [42, 46]. The receptor CCR7, as well as CXCR5 and CCR3 can 
be also expressed in leukaemia and lymphomas [47, 48]. Moreover, melanoma cells can 
express CCR9, CCR10, CXCR2 and CXCR3 [49-51]. The expression of chemokine 
receptors by tumor cells defines the metastatic tropism of cancer cells, depending on the 
chemokines produced at the metastatic site [6].  
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2.2  Chemokines and tumor infiltrating leukocytes 
 
One of the main functions of chemokines produced within the tumor is to promote 
leukocyte migration and infiltration (Figure 4). Leukocyte infiltrate is present in most 
tumors and, depending on the tumor and chemokines that are produced it can be different 
and includes cells of both myeloid and lymphoid origin. All of these infiltrating cells may 
have both pro-tumoral and anti-tumoral role, thus impacting on tumor progression [52]. 
For instance, monocytes and macrophages are mainly recruited by CCL2 and CCL5 as 
demonstrated by murine model of breast cancer, melanoma, colon cancer, esophageal 
carcinoma, and prostate carcinoma [53-59]. In humans, the level of CC-inflammatory 
chemokines correlates with the number of tumor associated macrophages (TAMs), 
metastatization and poor prognosis [60, 61]. Neutrophil infiltration is mediated by the 
production of CXC chemokines, such as CXCL1, CXCL2, CXCL5, and CXCL6, which 
are expressed by several tumor types [62-64]. Potent attractant of DCs is CCL20. Indeed, 
tumors expressing high level of this chemokine, such as pancreatic, renal, breast and 
papillary thyroid carcinoma, show a strong DCs infiltrate [65, 66]. Other chemoattractants 
of DCs are CCL5 and CXCL12 [67, 68]. Finally, tumors can be characterized by tumor-
infiltrating lymphocytes (TIL). TIL are mainly recruited by CXCL9 and CXCL10 by the 
interaction with CXCR3, and by CCL17 and CCL20 through the binding to CCR4. 
CXCR3 expressing cells recruited into the tumor are NK cells, CD4+ Th1 cells, and CD8+ 
cytotoxic T lymphocytes (CTL) which are important for an effective protective antitumor 
immune response [69-72]. Conversely, CCR4 positive cells are regulatory T cells (Treg) 
and polarized Th2 cells, which support tumor progression [73-75].  
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2.3  Chemokines and tumor growth 
 
It is well established that chemokines and their receptors have an important role in tumor 
growth (Figure 4). Indeed, chemokines produced within the tumor can bind receptors 
expressed on cancer cells and activate signaling pathways, such as MAPK/ERK, 
PI3K/Akt, and p53 pathways that are involved in the proliferation of tumor cells [76]. One 
of the most well studied chemokine is CXCL12. This chemokine binds the receptor 
CXCR4 and is involved in the growth of many cancers including glioma, breast cancer, 
ovarian cancer, small cell lung cancer, acute lymphoblastic leukemia and chronic B cell 
leukemia [77-81]. Another chemokine, CXCL8, plays a role in the proliferation of 
esophageal cancer cells, human gastric carcinoma cells and melanoma [50, 82, 83]. In 
addition, melanoma growth and progression can be induced by CCL27 and by the 
chemokines CCL19 and CCL21, which bind to CCR10 and CCR7, respectively [84, 85]. 
 
 
2.4  Chemokines and angiogenesis 
 
Angiogenesis is the process of formation of new blood vessels. It can be regulated by 
many chemokines and chemokine receptors, and plays a critical role in tumor progression 
(Figure 4). Chemokines can be either angiogenic or angiostatic, depending on their 
capability to promote or inhibit angiogenesis [12]. ELR+ chemokine, such as CXCL1, 
CXCL3, CXCL5, CXCL6, CXCL8, CXCL12, and the chemokines CCL2, CCL11 and 
CCL16, are potent angiogenic factors [86]. These chemokines promote angiogenesis both 
directly by the interaction with receptors expressed on endothelial cells, or indirectly 
throught the recruitment of leukocytes that provide angiogenic factors. For example, 
CXCL12 has been shown to bind CXCR4 on endothelial cells promoting cell migration 
and proliferation [87]. By contrast, CXCL5, CXCL6 and CXCL8 contribute to 
angiogenesis by attracting neutrophils which express the dedicate receptors CXCR1 and 
CXCR2 [50, 88]. CCL2 is involved in the recruitment of TAMs expressing CCR2 [89]. 
Neutrophils and TAMs are cells able to produce angiogenic factors such as VEGF-β, 
platelet derived growth factor (PDGF), transforming growth factor (TGF)-β and matrix-
metalloproteinases (MMP) such as MMP-2 and MMP-9 [90, 91]. Conversely, important 
angiostatic chemokines are CXCL4, CXCL9, CXCL10 and CXCL11, which inhibit 
neovascularization and endothelial cell proliferation [92, 93].  
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2.5  Chemokines and metastases 
 
Metastatic spread is the leading cause of death in people with cancer. Metastatization is a 
very complex and organ-specific process, during which malignant tumor cells enter into 
the blood or lymphatic circulation and, from the original primary tumor, spread to other 
organs. During metastatic spread, tumor cell migration shares many similarities with 
leukocyte trafficking and, accordingly, it is regulated by chemokines and their receptors 
[94]. Indeed, tumor cells can take advantage of chemokine signalling pathways by 
expressing appropriate chemokine receptors, which confer them the capability to migrate 
to distant sites [94]. The most studied chemokine axis is CXCR4/CXCL12 that is involved 
in the metastatic dissemination of tumor cells, for example breast cancer cells, which 
express CXCR4 and migrate in response to CXCL12 produced in lymph nodes (LNs), 
lung, brain, liver and BM [42]. Another chemokine receptor CCR7, which is important in 
normal immune response to recruit naïve T cells and DCs to LNs, can be also expressed in 
breast cancer, leukemia and lymphomas. In this context, CCR7 mediates the migration of 
tumor cells to LNs where the ligands CCL19 and CCL21 are produced [95, 96]. Moreover, 
it has been demonstrated that combined CCR7 and CXCR4 expression by breast cancer 
cells correlates with LN metastases [42]. Additional studies showed also the involvement 
of CCR9/CCL25 axis and CCR10-CCL27/CCL28 axis in promoting melanoma metastases 
to the small intestine and to the skin, respectively [42, 94, 97]. In a mouse model of 
melanoma induced by injection of B16F10 melanoma cells, the expression of CXCR3 by 
cancer cells mediated metastases to LNs [51]. Finally, the expression of CXCR5, the 
receptor for CXCL13, has been associated to frequent metastases to LNs in certain 
lymphomas [47]. 
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Figure 4: Chemokines and chemokine receptors expressed by cancer cells. Cancer 
cells express a vast repertoire of chemokines and chemokine receptors, which allow the 
interaction between cancer cell and tumor microenvironment [6]. 
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3. Atypical chemokine receptors 
 
Inflammation is a reaction of body to harmful stimuli consisting of an initiation stage, a 
maintenance stage, and a resolution stage [98]. Cytokines are important mediators of this 
process and their concentration needs to be tightly regulated and controlled for the correct 
development of the immune response and to avoid an exacerbated inflammation. As a 
consequence, vertebrates have adopted several mechanisms to control inflammation [99]. 
These mechanisms have been described to negatively regulate cytokine system acting both 
at transcriptional and post-transcriptional levels. One of the mechanisms by which the 
regulation at the post-transcriptional level is achieved, is represented by the activation of 
cytokine decoy receptors [14]. These receptors bind to their ligand with high affinity and 
specificity, but are structurally different from the canonical receptors and are unable to 
promote conventional signaling pathways. Among the group of decoy receptors, there is a 
subgroup of receptors, called atypical chemokine receptors (ACKRs) (Figure 5) [100, 
101]. ACKRs share many similarities with canonical chemokine receptors but show 
structural modification in the DRYLAIV motif and, as result, are unable to couple to G 
protein and to promote cell migration [100]. By contrast, ACKRs activate a β-arrestin 
dependent pathway and modulate chemokine bioavailability by transporting their ligands 
to intracellular degradative compartment, thus acting as chemokine scavengers [102-107]. 
According to the new nomenclature, the family of ACKRs include: ACKR1, previously 
called Duffy antigen receptor for chemokines (DARC); ACKR2, also known as D6 or 
CCBP2; ACKR3, alias CXC chemokine receptor 7 (CXCR7) or RDC1; and ACKR4, 
previously called CC chemokine receptor-like 1 (CCRL1) and also known as CCX-CKR 
[108]. Other molecules, such as CCRL2 and PITPNM3 have been tentatively included in 
the ACKR family as ACKR5 and ACKR6, respectively, but are awaiting for functional 
confirmation [108]. Although low level of ACKRs expression has been detected on 
leukocytes, ACKRs are mainly expressed by non-leukocyte cell types, such as lymphatic 
or vascular endothelial cells and erythrocytes [100, 109]. ACKR1 is expressed by 
erythrocytes, vascular endothelial cells, and Purkinje cells; ACKR2 by lymphatic 
endothelial cells (LECs), leukocytes, keratinocytes, and trophoblast; ACKR3 by 
hematopoietic cells, LECs, mesenchymal cells, and neuronal cells; and ACKR4 by LECs 
and epithelial cells [110-114].  
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Figure 5: Chemokine binding profile of ACKRs. ACKRs share many ligands with 
canonical chemokine receptors. They are similar to canonical chemokine receptors but 
show structural modification in the DRYLAIV motif [100].  
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3.1  ACKRs in the resolution of inflammatory response 
 
According with the crucial role of chemokines in inflammation, the biological activity of 
ACKRs has been demonstrated to be important in the resolution phase of the inflammatory 
response.  
ACKR1 binds more than 20 inflammatory chemokines belonging to the CC and CXC 
families, such as CCL2, CCL5, CCL7, and CXCL8. ACKR1 is expressed by erythrocytes 
and by endothelial cells and regulates the bioavailability of circulating chemokines, 
whereas ACKR2 expression by endothelial cells reduces chemokine concentration in the 
inflamed tissues and creates a functional gradient allowing proper leukocyte migration 
[115-117]. As a consequence, ACKR1 deficient mice are protected in different 
pathological contexts, such as acute kidney damage induced by ischemia or LPS, 
atherogenesis, and bone fracture. Indeed, in these models the lack of ACKR1 increased the 
level of circulating chemokines and induces the desensitization of the cognate receptors 
thereby reducing neutrophil and monocyte recruitment, and tissue damage [115, 118-124]. 
ACKR3 binds the chemokines CXCL11 and CXCL12 [125]. This receptor plays an 
important role in regulating CXCL12 availability for CXCR4 [126]. Moreover, ACKR3 
can modulate CXCR4 expression and function. Indeed, ACKR3 can form heterodimers 
with CXCR4 and can enhance or inhibit CXCL12- mediated signaling [126, 127]. ACKR3 
is upregulated in inflammatory conditions, and its expression is associated with a pro-
inflammatory phenotype, indeed ACKR3 enhances angiogenesis and promotes leukocyte 
extravasation [128, 129]. 
ACKR4 binds the homeostatic chemokines CCL19, CCL21, CCL25 and CXCL13. In the 
subcapsular sinus of LNs, ACKR4 creates functional gradients for CCL19 and CCL21, 
which are also ligand of CCR7, expressed by DCs [130]. By this way, ACKR4 promotes 
the migration of DCs and the induction of adaptive immune response [131]. 
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3.2  ACKRs in cancer 
 
In accordance with the crucial role of chemokines in cancer, preclinical and clinical 
observations provided evidence that the control of chemokine availability by ACKRs has 
an important role in cancer biology (Figure 6) [132]. For example ACKR1, in a mouse 
model of prostate cancer, has been demonstrated to have a protective role by limiting the 
level of the proangiogenic chemokines CXCL8 and CXCL2 [133]. ACKR3, in breast 
cancer, decreased CXCR4-mediated effects through the scavenging of CXCL12, thus 
limiting metastatic spread [134]. In tumors, expression of ACKRs was found in cancer 
cells themselves and can mediate different effects [132]. For example, expression of 
ACKR3 can promote tumor growth by the activation of signaling inducing the 
proliferation and by inhibiting apoptosis [135, 136]. In contrast, ACKR4 inhibits tumor 
growth and metastases by the degradation of its ligands [137-139]. 
                 
                            
 
Figure 6: Role of ACKRs in cancer: ACKR1, expressed by erythrocytes and endothelial 
cells, reduces angiogenesis and tumor growth. ACKR2 scavenges inflammatory CC 
chemokine, thus inhibiting inflammation, leukocytes recruitment, and tumor growth. 
ACKR3 expressed by tumor cells accelerates tumor growth, whereas ACKR3 on vascular 
endothelial cells degrades CXCL12, thus inhibiting tumor growth and metastases. ACKR4 
expressed by cancer cells constrains tumor growth [132]. 
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4. Atypical chemokine receptor 2 (ACKR2) 
 
In 1997 Steiner DF and Graham GJ have reported the cloning of a novel promiscuous 
receptor with high affinity binding for CC chemokines [140-142]. This receptor was 
named CCR9, CCR10 and D6, and the gene name ccbp2 was deposited in the GeneBank. 
Later, CCR9 and CCR10 nomenclatures were assigned to other receptors and D6 became 
the accepted name of this receptors. The name D6 referred to the coordinate on a multiwell 
plate, of the clone encoding this molecule [143]. However, according to the new 
nomenclature approved in 2014, D6 is now called ACKR2 and it is one of the best-
characterized atypical chemokine receptor [108].  
Although ACKR2 is highly promiscuous and binds a wide spectrum of chemokines, it 
selectively recognizes the agonists of the receptors CCR1, CCR2, CCR3, CCR4, and 
CCR5, which are CC-proinflammatory chemokines, such as CCL2, CCL3, CCL3L1, and 
CCL5 [141, 144]. Ligands of CCR6, CCR7, CCR8, CCR9, and CCR10 or other 
chemokine subfamilies are not recognized by ACKR2 [141].  
Moreover, ACKR2 efficiently recognizes and degrades only the biologically active form of 
these chemokines. For this reason, ACKR2 ligands were subdivided into three classes: CC-
inflammatory chemokines efficiently degraded, chemokines degraded with a less 
efficiency, and chemokines that are not degraded [145]. In particular, the chemokines 
degraded by ACKR2 are characterized by a proline in position 2 at the N-terminal, which 
can be cleaved by the protease CD26 [144]. For example, the chemokines CCL3 and 
CCL8, lacking this residue, are inactive, and thus they are not degraded by ACKR2 [145]. 
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4.1  ACKR2 structure and properties 
 
ACKR2 has a 7TM structure with a 30-35% range of similarity with canonical chemokine 
receptors, such as CCR1 and CCR5 [141]. However, ACKR2 shows some structural 
modifications in the transmembrane and C-terminal domains [146]. Indeed, it has a 
modified DRYLAIV motif mutated in DKYLEIV, which is conserved across the species 
and makes ACKR2 unable to couple to G-protein [147]. Moreover ACKR2 is 
characterized by the mutation of the aspartic acid into asparagine in the second 
transmembrane domain. Finally, the C-terminal domain of this receptor, starting from the 
amino acid 312 to the amino acid 384 is longer than the C-tail of conventional chemokine 
receptors (Figure 7). This domain is crucial for receptor internalization and recycling to the 
membrane after ligand stimulation [102]. In addition, it has a key role in preventing 
receptor degradation, indeed, its truncation decreases the stability of the receptor on cell 
membrane [148]. Despite all these modifications, the motif TxP, responsible for the 
activation of the receptor, is conserved [149].  
 
 
       
   
Figure 7: Structural differences between ACKR2 and canonical chemokine receptor: 
ACKR2 holds modifications in the transmembrane and C-terminal domains important for 
chemokine receptor signaling. In particular, ACKR2 has the DRYLAIV motif muted in 
DKYLEIV, the aspartic acid mutated into asparagine, and the C-terminus domain longer 
than C-tail of conventional chemokine receptors [150].  
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In basal conditions, ACKR2 is not highly expressed on the cell membrane and it is mainly 
stored in intracellular compartments. Upon chemokine engagement ACKR2 is mobilized 
from the intracellular compartments to the cell membrane through the Rab11+ vesicles 
[151, 152].  
In contrast to canonical receptors, which are internalized only after ligand engagement, 
ACKR2 is internalized constitutively in Rab5+ vesicles and is recycled back to the plasma 
membrane through a Rab4+ and a Rab11+ pathway [103]. 
In particular, it has been demonstrated that ACKR2 traffic is induced by a β-arrestin1-
dependent G- protein independent signaling pathway, involving the cascade of Rac1- p21-
activated kinase-1 (PAK1)-LIMK1, and inducing the phosphorylation of cofilin and actin 
rearrangement (Figure 8) [102].  
 
        
 
Figure 8: Actin dynamics sustain ACKR2 upregulation and degradatory activity. In 
basal condition ACKR2 is internalized in Rab5 vesicles and it is recycled to the plasma 
membrane through a Rab4/Rab11-pathway. Active cofilin maintains actin cytoskeleton 
organization and supports constitutive ACKR2 internalization and recycling. Stimulation 
with active ligands (purple) induces cofilin phosphorylation and its inactivation. This event 
induces   modification in the actin cytoskeleton organization, thus leading to ACKR2 up-
regulation and increasing chemokine degradation efficiency. Conversely, stimulation with 
neutral ligands (gray) does not change actin organization and cofilin activation, and does 
not affect ACKR2 distribution and scavenging efficiency [150].  
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4.2  Biological function of ACKR2 
 
The first studies to assess ACKR2 function were performed by in vitro approaches and 
provided data regarding the ability of ACKR2 to degrade its ligands.  
Next, the generation of monoclonal antibody against human ACKR2 provided the 
possibility to investigate the expression of the receptor. Nibbs and his colleagues 
demonstrated that ACKR2 is expressed by LECs of afferent lymphatic vessels (LVs) in 
barrier tissues such as skin, colon and lung [153]. Moreover, ACKR2 is strongly expressed 
in placenta by invading trophoblast and syncytiotrophoblast cells [111, 154]. Although at 
low level, the receptor has been found in some leukocyte populations, in particular in a 
subset of B cells and alveolar macrophages [111, 155, 156]. Finally, ACKR2 can be 
expressed by LVs in vascular tumors, in T cell malignances, including Kaposi’s sarcoma, 
and can be upregulated by peritumoral lymphatic cells in breast cancer [153, 157].  
Several studies in humans demonstrated that, at level of LVs, ACKR2 has increased 
expression in inflammatory conditions. For example, increased levels of ACKR2 
expression by LVs have been found in the alveolar parenchyma of patients with chronic 
obstructive pulmonary disease (COPD) and in psoriatic skin compared with healthy 
controls [158, 159]. Moreover, McKimmie et al. demonstrated that ACKR2 expression can 
be induced by growth factors and cytokines, such as IL-6 and IFN-γ, further indicating that 
this receptor is over-expressed in inflammatory contexts [160]. 
Despite these observations, only the generation of gene modified mice deficient for 
ACKR2 allowed studies to assess the role of ACKR2 expression in vivo [161]. 
 
 
4.2.1 The role of ACKR2 in homeostatic conditions 
 
The first evidences regarding the role of ACKR2 indicated that this receptor is mainly 
involved in the regulation of chemokine levels around afferent LVs, and ACKR2 is 
important to avoid an inappropriate accumulation of inflammatory leukocytes in the 
lymphatic system [162, 163]. McKimmie et al. demonstrated that ACKR2, by scavenging 
CC-proinflammatory chemokines, contributed to a selective presentation of CCR7 ligands, 
thus efficiently promoting the migration of DCs, crucial in maintaining immune 
surveillance [160]. Moreover, Savino et al. showed that, in resting condition, ACKR2 
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controls the traffic of CD11b+ Ly6C high monocytes with immunosoppressive phenotype 
and activity [164].  
Finally, ACKR2, reciprocally with CCR2, is able to regulate LV density. In particular, Lee 
et al. described an increased LV density in the ears, diaphragms and popliteal LNs in 
Ackr2-/- mice [165]. Additional studies revealed that this phenotype is mediated by pro-
lymphangiogenic macrophages present in proximity of developing LVs and recruited by 
CCL2; indeed, these macrophages are increased in Ackr2-/- mice and reduced in Ccr2-/- 
mice, which also have reduced LV density [165]. 
 
 
4.2.2 ACKR2 function during inflammation 
 
The role of ACKR2 has been investigated in a range of inflammatory models, in which 
ACKR2 emerges as a key regulator of inflammation, by controlling chemokine distribution 
and bioavailability (Figure 9). For example, in models of cutaneous inflammation, such as 
phorbol ester skin painting and subcutaneous injection of complete Freund’s adjuvant 
(CFA), Ackr2-/- mice developed an exacerbated inflammatory response [161, 166, 167]. 
Moreover, around the site of injection, Ackr2-/- mice showed increased areas of necrosis, 
increased angiogenesis and a higher number of infiltrating leukocytes compared to WT 
mice.  
A role for ACKR2 has been described also in the control of inflammation, antimicrobial 
resistance and activation of immune response during infection. Indeed, Di Liberto et al. 
demonstrated that Ackr2-/- mice, infected with Mycobacterium tuberculosis, showed 
increased number of infiltrating leukocytes, aberrant production of pro-inflammatory 
cytokines (TNF-α, IL-1β, INF-γ) and CC chemokines (CCL2, CCL3, CCL4 and CCL5), 
increased tissue damage and reduced survival [168]. Furthermore, the blockage of 
inflammatory CC chemokines, in Ackr2-/- mice, reversed the inflammatory phenotype but 
led to increased susceptibility to M. tuberculosis infection [168]. 
In models of maternal systemic inflammation, the expression of ACKR2 has been 
demonstrated to be important in dampening inflammation at materno-fetal barrier. In fact, 
in this context, Ackr2-/- mice displayed increased level of inflammatory CC chemokines 
and leukocytes associated with enhanced susceptibility to miscarriage [111, 154].  
Furthermore, the role of ACKR2 has been investigated in a model of colitis induced by the 
treatment of mice with dextran sulfate sodium (DSS). Vetrano et al. showed that Ackr2-/- 
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mice had increased intestinal inflammation characterized by increased level of 
inflammatory chemokines and infiltrating leukocytes compared to WT mice [156]. On the 
contrary, Bordon et al. observed that Ackr2-deficient mice have reduced clinical symptoms 
and tissue pathology in response to DSS, and correlated this phenotype to an increased 
production of IL-17A by T cells [169].  
In a murine model of graft versus host disease it has been found that the increased number 
of inflammatory monocytes with enhanced immunosuppressive activity protects Ackr2 
deficient mice from the development of the disease [164].  
Finally, controversial results have been published regarding the role of ACKR2 in the 
context of autoimmune diseases [170, 171]. 
 
 
4.2.3 ACKR2 and cancer 
 
Considering the relevance of ACKR2 in inflammatory conditions, the role of ACKR2 has 
been investigated in different models of cancer related inflammation (Figure 9).  Nibbs et 
al. found that in a model of skin carcinogenesis Ackr2-/- mice showed increased 
susceptibility to skin cancer, and they also had increased level of inflammatory CC 
chemokines and tumor infiltrating leukocytes [172]. Similar phenotype was observed in a 
model of colon cancer induced by Azoxymethane (AOM) and DSS treatment [156]. 
Since ACKR2 is expressed by different tumors, the role of ACKR2 expressed by cancer 
cells was assessed in a model of breast cancer and Kaposi’s Sarcoma. 
Wu et al. demonstrated that the overexpression of ACKR2 in breast cancer cells, is 
associated with decreased chemokine levels (CCL2 and CCL5), LV density and TAM 
infiltration; Savino et. al showed that the overexpression of ACKR2 in KS-IMM cells 
regulates the level of inflammatory CC chemokine within the tumor and inhibits monocyte 
differentiation and VEGFA production, thus reducing angiogenesis and tumor growth 
[173]. 
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Figure 9: ACKR2 in vivo activity. ACKR2 has important regulatory functions on 
inflammation. Scavenging chemokines, ACKR2 controls local inflammatory response, and 
promotes the successful migration of dendritic cells (DCs) to draining lymph nodes (LNs). 
ACKR2 functions have been demonstrated in Ackr2 deficient mice in different model of 
inflammation, including cancer related inflammation, allergy, infection, autoimmunity and 
graft versus host disease (GvHD) [150].  
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5. The hematopoietic system 
 
The hematopoietic system is a hierarchy of hematopoietic cell populations that became 
progressively mature and in which hematopoietic stem cells (HSCs) reside at the top  
(Figure 10) [174]. HSCs represent a rare population of cells in the BM and are 
characterized by an extensive self-renewal capability and pluripotency. Based on their 
temporal ability to generate the whole spectrum of mature blood cells, HSCs can be 
classified in long-term, intermediated-term and short-term hematopoietic stem cells (LT-
HSC, IT-HSC, ST-HSC) [174]. 
HSCs division can result in the production of additional HSCs or HPCs [175]. HPCs have 
a limited self-renewal capability and consist of: multipotent progenitors (MPPs), with no 
longer self-renewal ability and endowed with full lineage differentiation potential; and 
lymphoid-primed multipotent progenitors (LMPPs), common lymphoid progenitors 
(CLPs) and common myeloid progenitors (CMPs), in which multipotency is restricted to a 
specific lineage [174, 176, 177].  
CMPs give rise to granulocytes-macrophages progenitors (GMPs) and megakaryocyte-
erythrocyte progenitors (MEPs). The differentiation of CLPs, GMPs and MEPs give rise to 
the largest pool of hematopoietic cells which is made up of mature blood cells, including B 
cells, T cells, NK cells, NKT cells, monocytes, macrophages, granulocytes, platelets, 
erythrocytes, and DCs. Blood mature cells have no self-renewal capability, with the 
exception of certain B cell, and T cell subsets, tissue-resident macrophages and DCs [176, 
177].   
In mice, the fraction of multipotent cells is called LSK and is characterized as Lin- Sca-1+ 
c-kit+. Within the LSK fraction it is possible to distinguish, depending on the level of 
CD34 expression, the HSCs that are CD34- and MPPs that are CD34+. The CMPs are 
characterized as IL-7Rα- c-Kit+ Lin- Sca-1- and can be further fractionated on the basis of 
the expression of FcγRII and FcγRIII (CD16/CD32) and CD34. Finally, GMPs and MEPs 
that originate from CMP (FcγRII/IIIlo
 
CD34+) are characterized as FcγRII/IIIhi CD34+ and 
FcγRII/IIIlo CD34+, respectively [176].  
The process by which HSCs proliferate and differentiate into mature blood cellular 
components is called hematopoiesis [178]. In adult life haematopoiesis takes place into the 
BM [178]. However, in some cases, the liver, the thymus, and the spleen may assume an 
hematopoietic function; this is called extramedullary hematopoiesis and it is typical of fetal 
development, since bone and thus BM develop later [178].  Interestingly, macrophages that 
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have been traditionally known to originate from monocyte differentiation in the BM, may 
also derive from different precursors cells and do not have a monocytic progenitor [179]. 
Indeed, in embryos, tissue-resident macrophages in liver (Kupffer cells), brain (microglia), 
epidermis (Langerhans cells) and lung (alveolar macrophages), have been demonstrated to 
originate from precursors cells in the yolk sac and to be able to self-renew [180].  
 
             
 
Figure 10: The hematopoietic hierarchy: The hematopoietic system is a hierarchy of 
hematopoietic cell populations that became progressively mature and in which 
hematopoietic stem cells (HSCs) reside at the top. Depending on their temporal ability to 
differentiate, HSCs can be classified in long-term, intermediated-term and short-term 
hematopoietic stem cells (LT-HSC, IT-HSC, ST-HSC). HSCs division can result in the 
production of additional HSCs or into hematopoietic progenitor cells (HPCs) that give rise 
to the whole spectrum of mature blood cells [181]. 
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5.1  HSC bone marrow niche 
 
The niche is the tissue microenvironment that maintains and regulates stem cells [182, 
183]. During adulthood HSCs reside mainly within the BM, which is a complex organ, 
consisting of both hematopoietic and non-hematopoietic cell types, surrounded by 
vascularized and innervated bone. The interface between bone and BM is called 
endosteum. Near the endosteum, there is a rich supply of arterioles and sinusoids, which 
are small specialized and fenestrated vessels, allowing the cells to pass in and out the 
circulation, and providing a sort of barrier between the hematopoietic compartment and the 
peripheral circulation [178]. Within the BM, HSCs can be found in the endosteal zone 
closed to osteoblastic cells, or adjacent to sinusoids. Osteoblastic cells, together with 
osteoclastic and mesenchymal-derived stromal cells, form the osteblastic niche, where long 
term quiescent HSCs can be found [184]. Conversely, BM sinusoids represent the vascular 
niche that contains cells more prone to proliferate and differentiate (Figure 11). The 
function of quiescent HSCs is to replace active recycling HSCs in the vascular niche, 
whereas active HSCs replace lost quiescent cells in the osteblastic niche and also create a 
negative feedback to prevent the activation of quiescent HSCs [183, 185]. Interestingly, 
because of their localization and their capability to actively proliferate and differentiate, 
cells in the BM vascular niche are those immediately released to support the daily 
production of blood cells [186]. In BM, HSCs interact with osteoblast and endothelial 
cells. This interaction is mainly mediated by the CXCR4/CXCL12 axis. Indeed CXCL12, 
also known as stromal derived factor-1 (SDF-1), produced by stromal cells in the niche, 
binds to the receptor CXCR4 expressed by HSCs and induces their localization in both 
osteoblatic and vascular niches [187]. Another important factor is represented by stem cell 
growth factor (SCF) that binds to cKit on HSCs inducing their self-renewal [188]. In 
addition, other molecules such as P-selectin, E-selectin, and vascular cell adhesion 
molecules (VCAM-1), are expressed by niche stromal cells and control HSC maintenance 
and function by the interaction with their specific receptors on HSCs [186].  
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Figure 11: Proposed model of bone marrow (BM) osteoblastic and vascular niches of 
hematopoietic stem cells (HSCs). Long term quiescent HSCs can be found in the 
osteblastic niche, consisting of osteoblastic cells, together with osteoclastic and 
mesenchymal-derived stromal cells. Proliferating and differentiating cells are located in the 
BM sinusoids, which represent the vascular niche. Quiescent HSCs replace active 
recycling HSCs in the vascular niche, whereas active HSCs replace lost quiescent cells in 
the osteblastic niche and also create a negative feedback to prevent the activation of 
quiescent HSCs [186]. 
 
 
5.2 Regulation of HSC differentiation and mobilization 
 
The relationship between HSCs and their niches are highly dynamic and depend on the 
requirements of circulating hematopoietic cells. Indeed, in order to maintain physiological 
homeostasis and to achieve the balance between HSC renewal and differentiation, the 
niche elaborates also chemokines, cytokines and growth factors, which orchestrate 
hematopoietic development [183].    
These factors, such as hormone erythropoietin (EPO), SCF, IL-3, IL-6 and colony-
stimulating factors (CSFs), are important for the initial rounds of cell division and 
differentiation of HSCs in HPCs, and promote the formation of colonies that will give rise 
to more mature cellular component [189-193].   
CSFs are the major orchestrators of myelopoiesis, they were defined by their abilities to 
generate in vitro colonies of mature myeloid cells from BM precursor cells, and they 
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include: macrophage CSF (M-CSF; also known as CSF1), which supports macrophage 
differentiation from medullar precursors and differentiation of tissue macrophages; 
granulocyte-macrophage colony stimulating factor (GM-CSF; also known as CSF2) that 
stimulate the proliferation and differentiation into monocytes and DCs; and granulocyte 
colony stimulating factor (G-CSF; also known as CSF3), which is essential for the 
differentiation of neutrophil progenitors and precursors [193]. 
In steady state, myelopoiesis is regulated by the activation of several transcription factors. 
For example, G-CSF-induced granulopoiesis is mediated by CCAAT-enhancer-binding 
protein-α (C/EBPα), signal transducer and activator of transcription-3 (STAT3), and extra-
cellular regulated kinase 1 (ERK1), whereas M-CSF supports monocyte differentiation by 
activating transcription factors PU.1 and Interferon regulatory factor-8 (IRF8) [194-197]. 
Interestingly, it has been found that G-CSF, by increasing the number of neutrophils, also 
promotes the mobilization of HSCs [186]. These cells, released from BM, act as sentinel 
and rapid source of leukocytes in peripheral circulation [181, 186]. The mechanisms 
inducing their mobilization are aimed to inhibit cell-cell contacts between HSCs and BM 
niche cells, and include the cleavage of adhesion molecules and the desensitization of 
chemokine signaling, mainly the SDF1/CXCR4 axis [186, 198]. Proteolytic enzymes, such 
as Elastase and Cathepsin-G, play a major role in disrupting this axis by cleaving the N-
terminal signal sequence of SDF-1 and the receptor CXCR4 [198].  
HSC mobilization in response to G-CSF is due to the release of neutrophil proteases, 
including MMP-9, resulting in enhanced cleavage of ckit, SDF-1, CXCR4, VCAM and its 
receptor Very Late Antigen-4 (VLA-4) [186]. 
HSC recruitment in peripheral circulation is mediated by CXCL12 production at the 
periphery, and although HSCs express chemokine receptors, such as CCR3 and CCR9, 
they do not migrate in response to the ligands of these receptors [199]. 
 
 
5.3  The role of the chemokine system in myelopoiesis  
 
The role of chemokines and their receptors in myelopoiesis encompasses the regulation of 
proliferation as well as the survival of HSCs and HPCs [200, 201]. Based on several 
findings, at least 24 chemokines belonging to CC, CXC and C families, act as 
hematopoietic suppressor molecules, and they include: CCL3, CCL6, CCL19, CXCL5, 
CCL11, CCL20, CXCL6, CXCL2, CCL15, CCL16, CCL1, CXCL8, CXCL10, XCL1, 
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CCL2, CCL3, CCL23, CCL9/10, CXCL4, CCL21, and CCL25 [200, 202].  In addition, 
these chemokines had myelosuppressive activity in vivo. Indeed, they induced a dose 
dependent inhibition in the absolute number and cycling of HSCs [202, 203]. 
Among these chemokines, one of the best studied is CCL3/MIP-α, which was first 
identified as a suppressor molecule for spleen colony formation units (CFU-s), and then for 
multi-growth factor responding MPCs (e.g. CMP) [204, 205]. Conversely, CCL3 was 
shown to enhance the proliferation of more mature MPCs that respond to a single growth 
factor and are more committed progenitors [206]. To identify through which chemokine 
receptor CCL3 exerted its myelosuppressive activity, strategies for the cloning of CCL3 
receptor were developed. Interestingly, by this way ACKR2 was discovered [141]. 
However, given the redundancy of chemokine system, the role of CCL3 receptor in 
mediating chemokine myelosuppressive activity has been assessed by generating gene 
knock out mice deleted for specific chemokine receptor. K. Ottersbach and colleagues 
examinated the response of CCR1, CCR3, CCR5 and ACKR2 null BM cells to CCL3 and 
saw that BM cells had a full inhibitory response, indicating that none of CCL3 identified 
receptors was mediating the stem cell inhibitory effects of CCL3 [207]. Thus, yet 
unidentified receptor may be involved. 
Even if Ccr1-/- mice did not show reduced myelosuppression in response to CCL3, they 
elucidated the role of CCR1 in mediating myelopoietic effect of CCL3 on more mature 
MPCs (e.g. GMP) [206]. Indeed, Ccr1-/- MPCs stimulated to proliferate either by GM-CSF 
or M-CSF, in presence of CCL3, formed less colonies containing only granulocytes and 
macrophages compared to WT [206]. 
Again by using gene target mice, also the role of CCR2 and CXCR2 in the negative 
regulation of HPC proliferation was assessed. It was found that CCR2 controls the 
proliferation and programmed cell death (apoptosis) of HPCs [208]. Indeed, mice lacking 
CCR2 showed increased cycling status of MPCs in BM, and no difference in the absolute 
number of HPCs in BM and spleen compared to WT. This effect was demonstrated to be 
due to a balance between enhanced proliferation and enhanced apoptosis of Ccr2-/- HPCs 
[208]. The suppressive effect of CCR2 may be mediated by CCL2, CCL13 as well as 
CCL12, since these CCR2 ligands, but not CCL8 or CCL7, are myelosuppressive [200]. In 
Cxcr2-/- mice a selective insensitivity of MPCs to inhibition by CXCL8 and CXCL2, and a 
large expansion of MPCs have been described. Thus CXCR2 has been identified as a 
negative regulator of MCP proliferation by mediating the myelosuppressive activity of 
CXCL8 and CXCL2 [209].  
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5.4  The role of chemokine system in myeloid cell mobilization  
 
The chemokine system, in addition to control the proliferation of HSCs and MPCs, has a 
crucial role in the mobilization of mature myeloid cells, such as monocytes and 
neutrophils, from BM to the peripheral blood [2]. Depending on their activation states, 
monocytes and neutrophils can be distinguished in different cell subpopulations with a 
distinct pattern of chemokine receptor expression, which confers different migration and 
homing capabilities to the cells [210]. 
The release of monocytes from BM is mainly controlled by CCR2. In mice, this receptor is 
highly expressed on a subpopulation of blood monocytes, also distinguished for 
differential expression of the antigen Ly6C and the chemokine receptor CX3CR1 [210]. 
Ly6Chigh CCR2high/ CX3CR1low monocytes are the classical or proinflammatory monocytes 
that are recruited to inflammatory sites where they produce high levels of inflammatory 
cytokines and differentiate into tissue macrophages [210]. The expression of CCR2 by this 
cells starts during hematopoiesis, indeed as HSCs differentiate along the myeloid lineage, 
CCR2 expression increases and mediates also the trafficking of HSCs and MPCs to the site 
of inflammation [211]. The relevance of CCR2 in controlling inflammatory monocyte 
recruitment has been demonstrated by the fact that the number of these cells is markedly 
decreased in the blood of Ccr2-/- mice [212]. Moreover, analysis of mice lacking CCL2, 
CCL7, CCL12, or CCL8 plus CCL12 revealed that CCL2 and CCL7 are the CCR2 
agonists most critical for the maintenance of normal blood monocyte counts [213]. 
Conversely, Ly6Chigh CCR2low/ CX3CR1high monocytes are the non-classical, patrolling, or 
alternative monocytes [210, 214]. Their recruitment is mediated by CX3CR1 and they are 
considered to be important in tissue repair through the production of IL-10 and their 
differentiation in pro-resolving macrophages [214]. Whether the different subsets of 
monocytes originate as distinct populations from a common precursor or by transition from 
Ly6Chigh to Ly6Clow is a still debated issue.  
Monocytes also express CCR1 and CCR5, which are receptors for a variety of chemokines, 
including CCL3 and CCL5 [2, 215, 216].  In vitro transmigration assays have shown that 
CCR1 supports the arrest of monocytes in the presence of shear flow, CCR5 contributes to 
monocyte ‘spreading’, and both CCR1 and CCR5 mediate trans- endothelial chemotaxis 
towards CCL5 [217].  
Although less studied, also CCR6, CCR7, CCR8 and CXCR2 have been suggested to be 
involved in monocyte recruitment  [2]. 
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Regarding neutrophils, their trafficking from BM is regulated by the antagonistic activity 
of the chemokine receptors CXCR2 and CXCR4 [218]. Indeed, a constitutive expression 
of CXCL12 in the BM provides a retention signal for neutrophil precursors in the BM 
through the activation of their receptor CXCR4. CXCR4 down-regulation, induced by type 
I cytokines such as interferon (INF)-γ, IFN-α, GM-CSF and G-CSF, during medullary 
maturation, promotes the release of neutrophils from the BM [219]. This release has been 
demonstrated to be facilitated by the up-regulation of CXCR2 expression, in fact by using 
mouse mixed BM chimeras reconstituted with Cxcr2-/- and WT neutrophils, it was shown 
that Cxcr2-/- neutrophils are preferentially retained in the BM [218]. However CXCR4 
inhibition plays a dominant role in neutrophils mobilization, indeed neutrophils lacking 
both CXCR2 and CXCR4 displayed constitutive mobilization [218]. Interestingly, CXCR4 
that is down-regulated in circulating neutrophils may be up-regulated in senescent 
neutrophils to promote their homing back to the BM [220, 221]. 
Moreover, in various myeloid cell lines, CCR2 gene has been identified as one of the 
several targets of G-CSF during neutrophilic differentiation, and recently, CCR2 
expression, which was previously supposed to be restricted to monocytes, has been 
described in a subset of murine BM neutrophils [222, 223]. This expression has been 
demonstrated to influence neutrophil egress from the BM. Indeed, analysis performed in 
CCR2-RFP+/− mice (with intact CCR2 expression) and CCR2-RFP+/+ mice (CCR2 
deficient) had shown that CCR2-RFP+/+ mice have a small but statistically significant 
decrease in the number of neutrophils in the blood, LNs and spleen [223].  
 
 
5.5  Emergency granulopoiesis  
 
Myeloid cells are the first line of defence against invading organisms, and in steady state 
they are continuously generated to ensure their immediate availability for the containing of 
pathogens. However, during immunologic stress, such as systemic infection and cancer, 
the first-line of defense is overwhelmed and the demand of myeloid cells markedly 
increases. Most importantly, in this condition, neutrophils are consumed in large quantities 
[181]. To provide a supply to the increased demand of neutrophil, the hematopoietic 
system modifies the hematopoietic output through a process called emergency 
granulopoiesis, characterized by increased MPC proliferation and enhanced granulocytic 
differentiation within the BM [181]. 
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One of the most important cytokine regulating granulopoiesis is G-CSF as demonstrated 
by the strong reduction of circulating neutrophils in G-CSF and G-CSF receptor (G-CSFR) 
deficient mice [224] [225]. G-CSF production is regulated by IL-17A, which can be 
synthetized by γδ and NK cells, and by IL-23 that is produced by tissue-resident 
macrophages and DCs [226-229]. Since IL-17A is upstream of G-CSF, low levels of IL-
17A are associated with reduced expression of G-CSF and reduced release of neutrophils 
from the BM [229].  
In steady state, G-CSF, upon binding to G-CSFR that is expressed on MPCs, stimulates 
multiple intracellular signaling pathways via the activation of the Janus family kinases 
(JAK) and the STAT family proteins, such as STAT3 and STAT5 [194]. Moreover, G-CSF 
induces the activation of the major transcriptional regulator of steady-state granulopoieisis 
C/EBPα [230]. C/EBPα promotes the expression of many genes encoding proteins that are 
important for the proliferation of MPCs and granulocytic differentiation, for example the 
G-CSFR [231] (Figure 12). 
However, at the same time, both C/EBPα and STAT3-mediated G-CSF-induced signaling 
activate mechanisms to limit excessive cell proliferation. Indeed, C/EBPα also inhibits the 
expression of genes encoding for proteins, which are crucial for cell cycle progression, 
such as MYC, cyclin-dependent kinase (CDK)-2 and CDK4, whereas STAT-3 induces the 
expression of suppressor of cytokine signaling 3 (SOCS3) [232, 233]. SOCS3 is recruited 
to tyrosine residues on G-CSFR, and inhibits signal transduction through JAK–STAT3 
[233]. Furthermore, G-CSF stimulation induces the expression of the inhibitor of nuclear 
factor-κB (IκB) family member B cell lymphoma 3 protein (BCL-3) in a STAT3-
dependent manner [234]. BCL-3, originally identified as a proto-oncogene, also acts as an 
anti-inflammatory regulator by limiting the transcription of nuclear factor-κB (NF-κB)-
dependent genes [235, 236]. Thereby BCL-3 is required to limit MPC proliferation and 
differentiation in NF-κB dependent-manner [235, 236]. 
Conversely, emergency granulopoiesis is characterized by the activation of transcription 
factors different from those activated in steady-state granulopoiesis, and the mechanisms 
preventing excessive cell proliferation are lost [181]. Indeed, G-CSFR signaling through 
JAK leads to nuclear translocation of phosphorylated STAT3 (pSTAT3), which directly 
stimulates the expression of C/EBPβ that is the major transcriptional regulator of 
emergency granulopoiesis [237, 238]. C/EBPβ directly stimulates Myc transcription and 
also replaces C/EBPα at the Myc promoter through competition for binding, thereby 
leading to the inhibition of the transcriptional repression that C/EBPα exerts on Myc 
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expression [238]. As a result, the proliferative effects of C/EBPβ outweigh the anti-
proliferative effects of C/EBPα, resulting in enhanced MPC proliferation and neutrophil 
generation [181, 238] (Figure 12).  
The switch from steady state to emergency granulopoiesis can be induced by the pathogen 
sensing through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), 
and might be direct or indirect. Indeed, HSCs are capable to sense infection and 
inflammation, directly through the expression of PRRs or indirectly via inflammatory 
cytokines produced by other cells (both mature hematopoietic and non-hematopoietic 
cells) [181]. However, the signaling pathways that control the shift from C/EBPα-
dependent steady-state granulopoiesis to C/EBPβ-dependent emergency granulopoiesis are 
poorly understood. 
As well as all inflammatory conditions, also in tumor, cytokine production is prominently 
amplified, and as consequence, emergency granulopoiesis is activated [239]. In particular, 
tumor may either directly or indirectly produces G-CSF, indeed cancer cells themselves are 
a potent source of G-CSF, and also produce cytokines, which in turn induce the 
recruitment of tumor-associated leukocytes that are involved in G-CSF production. For 
example, TAMs are a well-known source of IL-1β, which is a potent inducer of IL-17/G-
CSF axis [240]. Recently, another factor named retinoic-acid-related orphan receptor 
(RORC1) has been identified as regulator of tumor-emergency granulopoiesis by 
suppressing Socs3 and Bcl3 and inducing C/EBPβ [241]. 
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Figure 12: Signal transduction and transcriptional activation in steady-state and 
emergency granulopoiesis. In steady-state G-CSFR signaling through the Janus family 
kinase (JAK) leads to the activation of C/EBPα that promotes the expression of many 
genes encoding proteins that are important for the proliferation of myeloid progenitor cells 
(MPCs) and granulocytic differentiation. C/EBPα simultaneously limits excessive 
proliferation by inhibiting the expression of Myc, cyclin-dependent kinase 2 (Cdk2) and 
Cdk4 that are crucial for cell cycle progression. Conversely, during emergency 
granulopoiesis G-CSFR signaling through JAK leads to nuclear translocation of 
phosphorylated STAT3 (pSTAT3), which directly stimulates the expression of C/EBPβ 
that is the major transcriptional regulator of emergency granulopoiesis. Directly binding to 
the proximal Myc promoter, C/EBPβ also inhibits the C/EBPα binding to the promoter, 
thereby suppressing the transcriptional repression exerted by C/EBPα on Myc expression 
[181]. 
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6. Neutrophils 
 
Neutrophils are key component of innate immunity and essential effectors of the 
inflammatory response [242]. In humans, they are the most abundant leukocyte population 
in circulation. The current paradigm is that circulating neutrophils have a short half-life in 
the bloodstream (6-12 h for mice and humans), followed by a rapid clearance from blood 
[243], and they are continuously produced and released from BM, especially in case of 
severe inflammation [181]. However, in vivo experiments have demonstrated that non-
circulating neutrophils can survive in tissue for several days [244, 245]. Moreover, tumor 
microenvironment can support their survival. Indeed, Mantovani and his colleagues 
showed that many cytokines produced by tumor cells prolong neutrophil survival in culture 
[246].  Neutrophils are characterized by a segmented nucleus and a cytoplasm enriched 
with granules and secretory vesicles. Three types of neutrophil granules can be 
distinguished; these are azurophilic (primary) granules, which are characterized by a high 
content of myeloperoxidase (MPO); specific (secondary) granules, which are characterized 
by a high content of lactoferrin; and gelatinase (tertiary) granules, which are characterized 
by a high content of MMP9 [242].  
During inflammation, neutrophils are the first cells to be recruited at the site of injury. 
They migrate by following a chemotactic gradient, and express two proteins, which are 
crucial for the recognition of endothelial inflammatory signals. Indeed, they express the P-
selectin glycoprotein ligand-1 (PSGL-1) and L-selectin, also known as CD62L; these 
molecules engage the P and E-selectins expressed by inflamed endothelial cells, resulting 
in neutrophil capture to endothelial wall. Then, the interaction of ICAM-1 on endothelial 
cells and LFA-1 on neutrophils, promotes neutrophil arrest and endothelial transmigration 
[243]. 
Upon arriving at the infection site, neutrophils can eliminate invading pathogen through 
different mechanisms. Indeed, they can release the antibacterial proteins (e.g. cathepsins, 
defensins, lactoferrin and lysozyme) contained in neutrophil granules either into 
phagosomes, upon pathogen phagocytosis or into the extracellular environment, thus 
killing pathogens by an intra- or extracellular mechanism, respectively. Moreover, 
neutrophils can fight pathogens by releasing reactive oxygen species (ROS, by NADPH 
oxidase activity) and reactive nitrogen species (RNS, by nitric oxide synthase activity), and 
by releasing neutrophil extracellular traps (NETs). NETs are fibers composed of processed 
chromatin and proteins, and they are an important strategy to immobilize invading 
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microorganisms, thus preventing their spread but also facilitating phagocytosis of trapped 
microorganisms [242].  
Since neutrophils are the first cells to arrive to the site of infection, in addition to kill 
invading pathogens, they also play a crucial role in establishing the proper environmental 
conditions to promote the activation of immune response. Indeed, they produce several 
cytokines and chemokines, which induce the recruitment of new immune cells, such as 
monocytes, macrophages, DCs, NK cells, and T cells [242].  
 
 
6.1 Neutrophil heterogeneity 
Recent findings have uncovered new interesting aspects regarding the biology of 
neutrophils. Indeed, studies analysing neutrophils in several inflammatory conditions have 
shown that these cells can display different degrees of maturation and activation, and they 
can have different functional properties being either immunosuppressive or pro-
inflammatory neutrophils [247]. These heterogeneous populations with distinct 
characteristics have been identified with a variety of name, including polymorphonuclear 
myeloid-derived suppressor cells PMN-MDSCs, low-density neutrophils (LDNs), and 
high-density neutrophils (HDNs) [248, 249]. PMN-MDSCs are morphologically and 
phenotypically similar to neutrophils, and they have been described as immature 
neutrophils with immunosuppressive activity [248]. LDNs are so called because after 
density gradient centrifugation of blood, they sediment within the low-density 
mononuclear cell layer rather than the expected HDN fraction [247, 249]. LDNs include 
both immature and mature cells with immunosuppressive or pro-inflammatory functions. 
Finally, HDNs have been described as mature and pro-inflammatory neutrophils [247, 
249]. However these ways to identify neutrophils are still matter of debate. 
 
6.2 Neutrophil subpopulations 
 
As well as for monocytes, in the last few years, the existence of different subsets was also 
described for neutrophils [250]. Indeed, neutrophils, after leaving the BM, enter into the 
circulation and acquire several phenotypic features depending on homeostatic or 
inflammatory conditions [251].  
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In mice, the majority of circulating neutrophils are Ly6Ghigh CD62Lhigh. When an 
inflammatory situation occurs, a fraction of circulating neutrophils down-regulates CD62L 
/L-selectin and CXCR2, and up-regulates ICAM-1/CD54, CCR1, and CCR2 [250]. These 
circulating neutrophils are activated and ROS, which confer them increased killing ability 
[91, 252]. 
Heterogeneity of circulating neutrophils has also been reported in the human setting. 
Indeed, in healthy donors is present a single population of neutrophils identified as 
CD66bbright/CD16high/CD62Lhigh/CXCR2high, whereas in inflammatory conditions, two 
populations can be found: CD66bbright/CD16dim/CD62Lbright that are immature forms of 
neutrophils and CD66bbright/CD16bright/CD62Ldim neutrophils that have an enhanced anti-
microbial function and ROS generation ability [253, 254]. 
Neutrophils after extravasation or after stimulation with proinflammatory cytokines, 
acquire a different pattern of chemokine receptor expression. They up-regulate the 
chemokine receptors CCR1, CCR2, CCR3, and CCR5 that promote respiratory burst 
activity and bacterial killing [255].  
Both in humans and mice, neutrophils recruited to the inflammatory site, can then 
transmigrate back into the circulation. These neutrophils are called reverse transmigrated 
neutrophils (rTEM), they express high levels of ICAM-1, and show enhanced ROS 
production. In addition they express low levels of the chemokine receptor CXCR1 [256]. 
Moreover, circulating neutrophils can spontaneously up-regulate the expression of 
CXCR4, which has been propose to mediate the migration of “senescent” neutrophils back 
to BM where the level of CXCL12 are constantly high [220]. 
 
 
6.3  Neutrophil polarization in cancer 
 
Neutrophils represent a high percentage of infiltrating leukocytes in many human cancers, 
and even though they have been mostly considered for their anti-microbial functions, 
recently they are emerging for their involvement in cancer biology [257, 258].  
In mice, it was demonstrated that tumor associated neutrophils (TAN) can exist in two 
different functional states: proinflammatory, antitumoral neutrophils (N1) and anti-
inflammatory tumor-promoting neutrophils (N2) [259].  
N1 neutrophils are hypersegmented, produce high levels of proinflammatory cytokines 
(e.g. TNF-α, CCL3) and radical oxygen species (H2O2, and NO) and are able to stimulate 
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T cell response. N1 polarization is determined by IFN-β and inhibited by TGF-β, which 
lead TANs to assume a proinflammatory and cytotoxic phenotype. Furthermore, 
neutrophils can be polarized to N1 by the proto-oncogene MET, which is induced on 
neutrophils by proinflammatory stimuli [260]. MET stimulation by its ligand HGF leads to 
neutrophil endothelial transmigration and NO production that promotes cancer cell killing 
and reduces tumor growth and metastases [260]. 
Conversely, N2 polarization is mediated by TGF-β and by IFN-β inhibition. Indeed, Ifn-β 
deficient mice showed enhanced growth of B16F10 melanoma and MCA205 fibrosarcoma 
tumors. This effect was due to increased infiltration of neutrophils expressing high levels 
of the transcription factors c-Myc and STAT3, known to regulate the expression of the 
proangiogenic factors VEGF and MMP9, and the homing receptor CXCR4 [261].  
Some studies have proposed that TAN infiltrating early tumors are N1 and they become 
N2 with tumor progression. In fact, in murine models of Lewis lung carcinoma (LLC) and 
mesothelioma (AB12), at early stages of tumor development TANs are cytotoxic toward 
tumor cells and produce high levels of TNF-α and NO, whereas in established tumors, 
these functions are reduced and TANs acquire a more pro-tumorigenic phenotype [262]. 
The same picture was found in an experimental model of breast cancer liver metastases, 
where infiltrating neutrophils showed an N2 phenotype during tumor progression and 
sustained tumor growth [263]. Similarly, in humans, TANs isolated from early stages of 
lung cancer as CD11b+CD15hiCD66b+ cells, resemble N1 neutrophils. Indeed, they have an 
activated phenotype (CD62Llo ICAM/CD54+), express a distinct repertoire of chemokine 
receptors (CCR5, CCR7, CXCR3, and CXCR4), produce high level of proinflammatory 
chemokines and cytokines (CCL2, CXCL8, CCL3, and IL-6), and express increased levels 
of costimulatory molecules that stimulate T cell proliferation [264]. 
 
 
6.4  Neutrophil protumoral functions 
 
A recent meta-analysis of published papers showed that the presence of neutrophils in 
tumor tissues represents a poor prognostic indicator in various cancers [265]. Indeed, as 
shown in several studies, TANs are able to sustain cancer progression through several 
mechanisms.  
TANs release enzymes, contained in their granules, such as neutrophil elastase, MMP8 
also known as neutrophil collagenase, and MMP9 also known as neutrophils gelatinase B, 
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that promote tumor cell invasion by remodeling extracellular matrix (ECM) or directly 
acting on tumor cells [266]. Neutrophils also produce cytokines and growth factors (EGF, 
TGF-β, PDGF, HGF, VEGF) with pro-tumoral activity. Indeed, hepatocyte growth factor 
(HGF) has been shown to promote the invasion of human pulmonary adenocarcinoma cells 
[267]. Moreover, neutrophils can promote the angiogenesis through the release of MMP9 
that activate VEGF, and through the production of oncostatin M, a member of IL-6 family, 
known to induce the production of VEGF [268, 269]. Additionally, neutrophils enhance 
tumorigenesis through the release of ROS and RNS that contribute to DNA damage and 
genetic instability [270]. 
Furthermore, neutrophils can produce molecules, which are able to directly promote tumor 
cell proliferation. For example, neutrophil elastase, prostaglandin E2 (PGE2) and 
leukotrienes activate intracellular signaling cascades, which lead to tumor cell proliferation 
[271, 272]. In particular, rachidonate 5-lipoxygenase (ALOX-5) mediated leukotriene 
synthesis supports the proliferation of metastasis initiating cells in different mouse model 
of breast cancer [273]. 
Neutrophils can promote tumor metastasis by facilitating the adhesion of tumor cells to 
endothelial cells at the extravasation site. Indeed tumor cells can be trapped within the 
NETs and increase their adhesion to hepatic and pulmonary microvasculature. NETs can 
also promote cancer cell proliferation by inhibiting apoptosis [274]. 
Finally, neutrophils exert their protumoral activity by inhibiting the antitumoral immune 
responses. In fact, upon CXCL8 stimulation, neutrophils produce arginase 1 (Arg1), an 
inhibitor of T cell function [275]. It was also described that neutrophils express 
programmed death-ligand 1 (PD-L1), which suppresses T-cell proliferation [276]. 
Moreover, neutrophils were shown to produce TGF-β, a cytokine with immunosuppressive 
effect on other immune cells [277]. 
 
 
6.5  Neutrophil antitumoral functions 
 
Despite the predominant outline of neutrophils protumoral functions, other studies revealed 
the capabilities of these cells to exert anti tumoral effects [278].  
For example, although neutrophils, by producing ROS, promote cell death and tissue 
damage in the tumor microenvironment, they can be cytotoxic against tumor cells. 
Accordingly, it has been described that neutrophils can inhibit the metastatic seeding of 
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breast carcinoma cells in the lungs by producing high levels of hydrogen peroxide and 
killing tumor cells [252].   
Another killing mechanism is reported for IFN-activated neutrophils that release 
biologically active TNF-related apoptosis-inducing ligand (TRAIL/APO2 ligand), a 
molecule that exerts a selective apoptotic activity toward tumor cells [279, 280]. Moreover, 
neutrophils also mediate Fas-mediated apoptosis of cancer cells [281]. 
Finally, neutrophils are able to promote the adaptive immune response against tumors. 
They can either directly stimulate T cells through the expression of OX-40L and 4-1BBL, 
which are co-stimulatory molecules that enhance the proliferation of CD4+ and CD8+ T 
cells, or indirectly via cytokine and chemokine-mediated leukocyte recruitment [264, 282]. 
 
 
6.6  Insights into the role of chemokine system in neutrophil recruitment and 
effector functions in tumors 
 
Recently, it is emerging that the differential expression of chemokine receptors on 
neutrophil subpopulations, can affect not only their recruitment but also their effector 
functions [258]. For example, it has been shown that CCR2 is not only important for 
neutrophil mobilization and tumor infiltration but also for neutrophil antitumoral activity. 
Indeed CCR2+ neutrophils exert an anti-metastatic activity by producing ROS in a CCR2-
depent manner [252]. Similarly, CXCR2 that also have an important role in neutrophil 
mobilization promotes tumor infiltration of neutrophils that produce pro-angiogenic 
factors, which support tumor growth. Accordingly, the expression of CXCR2 ligands by 
tumors plays a role in promoting the development and metastases of several cancer types 
[63, 283]. CXCL5 was found to recruit neutrophils that support tumor growth in a mouse 
model of hepatocellular carcinoma (HCC) [64]. CXCL6 induces neutrophil infiltration and 
increases tumor angiogenesis and melanoma growth, whereas CXCL1 and CXCL2 recruit 
neutrophils expressing S100SA8/9 that promote cancer cell survival and resistance to 
chemotherapy [62, 63]. As a consequence, the blockage of CXCR2 signaling results in 
inhibited infiltration of neutrophils into the tumor, retarded tumor growth and reduced 
angiogenesis, in both B16F10 and MCA205 tumor models [284], whereas in breast 
carcinoma model CXCR2 inhibition reduces the recruitment of neutrophils into the tumor 
and increases the efficacy of chemotherapy [62].  
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Although targeting of CXCR2 has a beneficial effect on tumor growth, opposing results 
were published on metastases. In renal cell carcinoma (RCC) CXCL5 and CXCL8 
produced by tumor cells have been described to recruit antimetastatic neutrophils that 
inhibit the seeding of tumor cells [285]. 
Thus, it is still unclear if CXCR2 expression can be considered an N1 or N2 marker. 
CXCR2 expression in murine neutrophils is not modified by the treatment with the N1 
polarizing cytokine IFN-β, whereas in human lung patients CXCR2 is down-regulated in 
TANs with N1 phenotype [264, 284]. 
Finally, it has been found that CXCR4 is down-regulated by IFN-β stimulation, and is 
overexpressed in a subpopulation of circulating neutrophils promoting angiogenesis and 
tumor progression, thus suggesting that CXCR4 is up-regulated in N2 neutrophils [261]. 
 
 
                                   
 
Figure 13: Neutrophil plasticity in cancer: N1 polarization is induced by IFN-β and 
inhibited by TGF-β, whereas TGF-β stimulation and IFN-β inhibition promote N2 
polarization. N1 and N2 phenotype can be distinguished by the expression of distinct 
molecules and chemokine receptors, and by the production of different chemokines and 
inflammatory mediators [258]. 
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Aim of the thesis 
 
ACKR2 plays an essential role in the regulation of inflammatory chemokine concentration, 
and its activity has been demonstrated to be important to promote the appropriate 
leukocyte recruitment into inflamed tissue and to sustain the resolution of inflammatory 
response in several inflammatory conditions. The general objective of this PhD thesis was 
to gain insight into the role of ACKR2 in BM mobilization and effector functions of 
myeloid cells.  
Thus, taking advantage from Ackr2-gene targeted mice, FACS analysis, RT-PCR, primary 
cell cultures and cell lines, the purpose of this investigation was to address the role ACKR2 
in the regulation of neutrophil and monocyte mobilization, the contribution of ACKR2 in 
the regulation of HPC differentiation, the impact of ACKR2 expression on CC chemokine 
receptor expression and finally the relevance of the data obtained in a model of 
experimental metastasis in order to address the role of myeloid cells in this context. 
 
 
 
 
 
 
 
 
 
 
 
	   46	  
Material and methods 
 
1. Animals 
Ackr2-/- mice have been generated as described and were maintained on a C57BL/6J 
genetic background [161]. WT mice were obtained from Charles River Laboratories, 
Calco, Italy. All colonies were housed and bred in the Specific Pathogen Free (SPF) 
animal facility of Humanitas Clinical and Research Center in individually ventilated cages. 
Mice used for experiment were from 8 to 12 weeks old. Procedures involving animal 
handling and care were conformed to protocols approved by the Humanitas Clinical and 
Research Center (Rozzano, Milan, Italy) in compliance with national (D.L. N.26, 4-3-
2014) and international law and policies (EEC Council Directive 2010/63/EU, OJ L 
276/33, 22-09-2010; National Institutes of Health Guide for the Care and Use of 
Laboratory Animals, US National Research Council, 2011). The study was approved by 
the Italian Ministry of Health (approval n. 88/2013-B, issued on the 08/04/2013). All 
efforts were made to minimize the number of animals used and their suffering. 
 
2. Chemokine administration 
For mobilization experiments, mice were intraperitoneally injected with 3 µg of CCL3L1 
(R&D) per mouse and one hour later, blood was collected for flow cytometry analysis. 
To evaluate the frequency of monocytes in BM sinusoids, mice were injected with 3 µg of 
CCL3L1 (R&D), and 2 minutes before the end of experiment they were intravenously 
injected with 1 µg Ly6C-PE (clone AL21, BD Bioscience) antibody. 
 
 
3. AMD3100 administration 
AMD3100, the competitive inhibitor of CXCR4, was obtained from Sigma-Aldrich, Inc. 
(St. Louis, MO). Each mouse received a daily subcutaneous injection of AMD3100 (4 
mg/kg) or PBS for the entire duration of the experiment. 
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4. Cell lines  
HL-60 cells were purchased from ATCC and growth in Iscove's Modified Dulbecco's 
Medium (IMEM) (Lonza), 20% FBS (Sigma), 1% Penicillin/Streptomycin (Lonza), 1% L-
glutamine (Lonza), 1% Sodium Pyruvate (Lonza). B16F10 cells expressing Melan A were 
kindly gift by Massimiliano Mazzone from VIB Vesalius Research Center (Leuven), and 
were growth in DMEM (Lonza), 10% FBS (Sigma), 1% Penicillin/Streptomycin (Lonza), 
1% L-glutamine (Lonza), 1% HEPES (Lonza). 
 
 
5. HL-60 transfection 
HL-60 cells were transfected by using the Nucleofector Kits for HL60 (LONZA) 
according to the manufacturer’s instructions. 
 
 
6. Tissue collection 
Blood was collected from the retro-orbital plexus and by cardiac puncture as previously 
described [286]. Briefly, blood was collected and transferred in 2KD-EDTA spray coated 
tube (BD Bioscience). Erythrocytes were lysed with ACK buffer. After washing in FACS 
buffer (PBS-/-, 1% BSA, 0,05 % sodium azide), the cells were stained for flow cytometry 
analysis. BM cells were flashed out from the bone cavity of femurs and tibias of C57BL/6J 
WT and Ackr2-/- mice.  Total BM cells were filtered through a 70 µm cell strainer. 
Erythrocytes were lysed with ACK buffer. After washing in FACS buffer, the cells were 
stained for flow cytometry analysis. 
 
 
7. Generation of bone marrow chimeras 
WT and Ackr2-/- mice were lethally irradiated with a total dose of 900 cGy. Then, 2 hours 
later, mice were injected in the retro-orbital plexus with 4x106 nucleated BM cells obtained 
by flushing of the cavity of a freshly dissected femur from WT or Ackr2-/- donors. 
Recipient mice received gentamycin (0.8 mg/ml in drinking water) starting 10 days before 
irradiation and maintained during 2 weeks. Blood was analysed 15 weeks after BM 
transfer.  
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8. FACS analysis 
The phenotypic analysis of cells was performed using the combination of following 
antibodies: anti-CD45-PerCP or –V450 (Clone 30-F11), anti-CD11b-PB or PE (clone 
M1/70), anti-Ly6G-PeCy7 or -FITC (clone 1A8), anti-Ly6C-FITC (clone AL-21), anti- 
F4/80-APC (clone CI:A3-1), anti-ICAM-1-APC (clone YN1/1.7.4), anti-CD62L-PE (clone 
MEL14), anti-Gr-1-APC (clone RB6-8C5), anti-CCR2 (gently gift by Matthias Mack) , 
anti-CXCR4-PE (clone 2B11), anti-Lin cocktail-eFluor 450 (clone 17A2, RA3-6B2, 
M1/70, TER-119, RB6-8C5), anti-Sca-1-PeCy7 (clone D7), anti-c-Kit-APCeFluor780 
(clone 2B8), anti-CD34-FITC (clone RAM34), anti-FcγR-PerCP-Cy5.5 (clone 93), and 
isotype-matched control antibodies. Antibody anti-CCR2 was not fluorochrome-labelled, 
thus for CCR2 staining, after incubation with the rat anti-mouse CCR2, the cells were 
incubated with a monoclonal biotinylated mouse anti-rat IgG2b and finally with 
Steptavidin-PE or PB. All antibodies were purchased from BD Bioscience, BioLegend, 
eBioscience or AbD Serotec. Cell viability was determined by Aqua LIVE/Dead-405nm 
staining (Invitrogen), negative cells were considered viable. The absolute number was 
determined by using TruCount beads (BD Biosciences) according to the manufacturer’s 
instructions. Flow cytometry was performed by using FACSCanto II (BD Bioscience) and 
LSR Fortessa (BD Bioscience). Data were analyzed with FACSDiva software (BD 
Bioscience) and FloJo Software (Tree Star). 
 
 
9. Hematopoietic progenitor isolation and culture 
Lineage negative cells (Lin-) were isolated from BM WT and Ackr2-/- using Lineage Cell 
Depletion Kit, mouse (Miltenyi Biotec), and the LS columns from Miltenyi Biotec 
according to manufacturer’s instructions. Negative fraction of cell preparation was stained 
with anti-Streptavidin-PB, anti-Sca-1, anti-c-kit, anti-CD34 and anti-FcγR antibodies and 
sorted with FACSAria III (BD Bioscience). Antibody anti-Streptavidin was used to further 
discriminate Lin+ cells that were not accurately depleted by the Lineage Cell Depletion Kit. 
After sorting, LSK, identified as Lin-, Sca-1+, cKit+, were seeded in round bottom 96 wells 
plate (1x104 cells/well) in IMDM (Lonza) supplemented with 10% FCS (Sigma), 1% 
Glutamine (Lonza), SCF 10ng/ml (Peprotech), IL-6 10 ng/ml (Peprotech), IL-3 10 ng/ml 
(Peprotech).  
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10. Evaluation of lung metastases 
Lung metastases were evaluated 10 days after intravenous injection of 2x105 B16-F10 
cells, and they were macroscopically counted as dark nodules on the lung surface. 
 
 
11. Monocyte and neutrophil depletion  
To inhibit monocyte differentiation, mice were treated the day before the injection of 
B16F10 with 100 µg of αCD115 antibody (clone AFS98, Bioxcell) and then, every two 
days with 100 µg for the entire duration of the experiment. To deplete neutrophil, mice 
were treated the day before the injection of B16F10 with 200 µg of αLy6G antibody (clone 
1A8, Bioxcell) and then, every three days with 100 µg for the entire duration of the 
experiment. 
 
 
12. Neutrophil isolation  
Neutrophils were isolated from BM WT and Ackr2-/- using the Neutrophil Isolation Kit, 
mouse (Miltenyi Biotec) and the autoMACS Pro separator (Miltenyi Biotec), according to 
manufacturer’s instructions. The purity of neutrophil cell preparation was evaluated by 
flow cytometry using antibodies anti-CD45, anti-CD11b and anti-Ly6G. Neutrophils were 
used only when the frequency of contaminating leukocytes in neutrophil preparations was 
<6% for neutrophil adoptive transfer, and <3% for RT-PCR analysis.  
 
 
13. Neutrophil adoptive transfer 
Neutrophils were isolated from BM WT and Ackr2-/-. WT mice were intravenously injected 
with 5x106 neutrophils of WT or Ackr2-/- mice every 3 days for the entire duration of the 
experiment. 
 
 
14. Quantitative PCR 
Total RNA was extracted from HPCs with miRNA easy Mini kit (Qiagen), and from HL-
60 cells, neutrophils and BM total cells by using Trizol reagent (Invitrogen) following the 
manufacturer’s recommendations. Reverse transcription was done using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR (RT-
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PCR) was performed with TaqMan Gene Expression Assays using TaqMan fast advanced 
Master Mix, or with SYBR Green method using SybrGreen PCR Master Mix (Applied 
Biosystems), and was conducted in a CFX Connect Real-Time PCR Detection System 
(BioRad). For TaqMan Gene Expression Assays (Thermo Fisher) specific probes for 
murine ACKR2 (Mm_00445551_m1), murine CCR2 (Mm_00438270_m1), murine CCR1 
(Mm01216147_m1), murine CCR5 (Mm04207879_m1), murine CXCR4 
(Mm_01292123_m1), murine β-Actin (Mm_00607939_s1), murine GAPDH 
(Mm_99999915_g1), murine VEGFA (Mm00437306_m1), murine TNFα 
(Mm00443258_m1), murine Alox5 (Mm01182747_m1), murine Arg1 
(Mm_00475988_m1), human ACKR2 (Hs_00174299_m1), human CCR2 
(Hs00704702_s1), human CXCR4 (Hs_00607978_s1), human CD11b 
(Hs00355885_m1), and human GAPDH (Hs_99999905_m1) were used. For SYBR 
Green Assay, primers for STAT3, CEBPβ, PU.1, IRF8, Bcl3, Socs3, and RORC1 mRNA 
were gently given by Antonio Sica and are available upon request [241]. Relative mRNA 
expression was determined by using the Δ2Ct method (Applied Biosystems, Real-Time 
PCR Applications Guide). Data were normalized based on the GAPDH or β-Actin 
expression determined in the same sample.  
 
 
15. Statistics 
All values were expressed as mean ± SEM. Unpaired Student’s t test, was used as 
specified. P≤ 0.05 was considered significant. Statistics were calculated with GraphPad 
Prism version 6, GraphPad Software. 
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Results 
 
1. Ackr2-/- mice display increased mobilization of myeloid cells 
 
Given the relevance of the chemokine system in controlling leukocyte trafficking and BM 
mobilization, we addressed the effect of ACKR2 chemokine scavenging in a mouse model 
of BM mobilization. To this purpose, we used CCL3L1, which is an inflammatory 
chemokine, binding ACKR2 and other CC chemokine receptors, and known to induce a 
rapid mobilization of both neutrophils and monocytes [287]. We intraperitoneally injected 
CCL3L1 into WT and Ackr2-/- mice and, one hour after chemokine injection, blood and 
BM were collected. As expected, CCL3L1 injection led to an increasing of neutrophils 
(Figure A) and monocytes (Figure B) into the blood of WT and Ackr2-/- mice. However, 
the absolute number of these cells was higher in Ackr2-/- mice compared to WT.  Moreover, 
when we evaluated the frequency of neutrophils and monocytes into the BM of WT and 
Ackr2-/- animals, we observed that CCL3L1 injection caused a decrease in the frequency of 
these cells in the BM, and this reduction was more prominent in Ackr2-/- mice (Figures 1C 
and 1D). These data indicate that Ackr2-/- mice show increased CCL3L1-induced 
mobilization of myeloid cells from the BM. 
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Figure 1: Increased monocyte and neutrophil chemokine-induced mobilization in  
Ackr2-/- mice. A, B: Absolute number of circulating neutrophils (A) and inflammatory 
monocytes (B) in the bloodstream of WT and Ackr2-/- mice. C, D: Frequency of BM 
neutrophils (C) and inflammatory monocyte (D) in basal conditions and 1 hour after i.p. 
injection of CCL3L1. Neutrophils were identified as CD45+CD11b+Ly6G+, whereas 
inflammatory monocytes as CD45+CD11b+Ly6Chigh. Data were represented as (mean ± 
SEM). *: p<0.05, **: p<0.01, ***: p<0.001. 
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2.  Ackr2-/- mice have increased number of monocytes in BM sinusoids 
 
Then we evaluated whether ACKR2 was affecting the number of cells in the BM 
sinusoids, which represent the BM vascular niche. Differently from quiescent HSCs, which 
are located in the BM osteblastic niche, actively proliferating and differentiating HPCs, 
and mature cells immediately release into the blood are located in the BM sinusoids. To 
evaluate the number of cells in this compartment, we intraperitoneally injected CCL3L1 
into WT and Ackr2-/- mice, and 2 minutes before the end of experiment, we intravenously 
injected an anti-Ly6C labelled antibody. Being anti-Ly6C injected intravenously, when we 
harvested BM, this technic allowed us to identified only Ly6C+ cells located in BM 
vascular compartment [288].  By analyzing the frequency of Ly6C+ cells in the BM, we 
saw that it was higher in Ackr2-/- mice compared to WT, thus indicating that Ackr2-/- mice 
had more cells located in the BM sinusoids (Figures 2A and 2B). These results suggest that 
the increased mobilization observed in Ackr2-/- mice could be due to a bigger pool of cells 
ready to be release in the BM vascular niche. 
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                                                                 B 
                                                         
 
Figure 2: Increased number of monocytes in the BM vascular niche of Ackr2-/- mice 
upon CCL3L1 injection. A, B: Representative histogram of FACS analysis (A) and 
frequency (B) of Ly6C labelled monocytes of WT and Ackr2-/- mice 1 hour after i.p. 
injection of CCL3L1. Ly6C antibody was injected i.v. 2 minutes before the end of the 
experiment. Monocytes were identified as CD45+CD11b+Gr1+Ly6G-. Data were 
represented as (mean ± SEM). **: p<0.01, Ackr2-/- versus WT. 
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3.  ACKR2 expression in the hematopoietic compartment affects myeloid cell 
mobilization from BM 
 
To understand whether the increased mobilization observed in Ackr2-/- mice was due to the 
lack of ACKR2 in hematopoietic cells or BM stromal cells, we performed BM chimera 
experiments by transplanting WT or Ackr2-/- BM cells into WT and Ackr2-/- hosts. To 
ensure the appropriate BM reconstitution, we performed the BM mobilization experiment 
15 weeks after BM transfer, and we saw that both WT and Ackr2-/- animals, transplanted 
with Ackr2-/-, but not with WT hematopoietic cells, had an increased mobilization of 
myeloid cells in response to CCL3L1, as indicated by the increased number of circulating 
neutrophils (Figure 3A) and monocytes (Figure 3B) into the blood of those mice. These 
results indicate that the increased chemokine-induced mobilization of Ackr2-/- mice is due 
to the absence of ACKR2 in the hematopoietic compartment. 
 
 
                           A                  B 
                 
 
Figure 3: Increased myeloid cell mobilization in mice transplanted with BM Ackr2-/- 
cells. A, B: Absolut number of neutrophils (A) and inflammatory monocytes (B) in the 
bloodstream of WT and Ackr2-/- mice reconstituted either with WT or Ackr2-/- BM after i.p. 
injection of CCL3L1. Neutrophils were identified as CD45+CD11b+Ly6G+, whereas 
inflammatory monocytes as CD45+CD11b+Ly6Chigh. Data were represented as (mean ± 
SEM). *: p<0.05. 
 
 
 
 
 
0
20
40
60
80
100 *** ***
*
C
D
11
b+
 L
y6
G
+ 
/ C
D
45
+ 
(c
el
l x
 1
02
/µ
l)
0
20
40
60
80 ** ***
**
C
D
11
b+
 L
y6
G
+ 
/ C
D
45
+ 
(%
)
0
5
10
15
20 *** ***
*
**
C
D
11
b+
 L
y6
C
hi
 / 
C
D
45
+ 
(c
el
l x
 1
02
/µ
l)
0
5
10
15 *** ***
*
**
C
D
11
b+
 L
y6
C
hi
 / 
C
D
45
+ 
(%
)
A B
C D
E F
WT
 →
 W
T
Ac
kr2
-/-  →
 W
T
WT
 →
 A
ck
r2
-/-  
Ac
kr2
-/-  →
 A
ck
r2
-/-
0
2
4
6
8
10
*
* *
C
D
11
b+
 L
y6
C
hi
 / 
C
D
45
+ 
(c
el
l x
 1
02
/µ
l)
WT
 →
 W
T
Ac
kr2
-/-  →
 W
T
WT
 →
 A
ck
r2
-/-
Ac
kr2
-/-  →
 A
ck
r2
-/-
0
10
20
30
40
50
0,0807
*
C
D
11
b+
 L
y6
G
+ 
/ C
D
45
+ 
(c
el
l x
 1
02
/µ
l)
PBS     CCL3L1
WT
PBS     CCL3L1
Ackr2-/-
PBS     CCL3L1
WT
PBS     CCL3L1
Ackr2-/-
PBS     CCL3L1
WT
PBS     CCL3L1
Ackr2-/-
PBS     CCL3L1
WT
PBS     CCL3L1
Ackr2-/-
	   56	  
4. ACKR2 is expressed by hematopoietic progenitors 
 
Since BM chimera experiments demonstrated that the absence of ACKR2 in cells of the 
hematopoietic compartment was responsible for the increased myeloid mobilization 
observed in Ackr2-/- mice, we evaluated ACKR2 expression in hematopoietic cells in the 
BM by RT-PCR analysis. In particular, we analyzed the expression of ACKR2 in sorted 
hematopoietic precursors of the myeloid lineage identified as shown in Figure 4A. We 
found that ACKR2 was expressed by Lin-, Sca-1+, cKit+ (LSK) cells and its expression was 
down-regulated in the more mature CMP (Lin-, Sca-1-, cKit+, CD34+, FcγR+) and GMP 
(Lin-, Sca-1-, cKit+, CD34+, FcγRhigh) (Figure 4B). We also analyzed the expression of 
CCR2 in these populations and we confirmed data already reported in literature, indeed 
CCR2 was weakly expressed by LSK and its expression increased during maturation 
through myeloid lineage [211] (Figure 4C). Thus, ACKR2 is expressed in most immature 
progenitors to faint thereafter in more mature MPCs in contrast with the canonical 
chemokine receptor CCR2, whose expression is acquired during maturation.  
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Figure 4: Expression of ACKR2 and CCR2 in hematopoietic progenitors. A: Gating 
strategy used to identify LSK, CMP, and GMP. B, C: Analysis of the expression of 
ACKR2 (B) and CCR2 (C) by RT- PCR in LSK, CMP and GMP cells sorted from BM of 
WT mice. Data were relative to β-actin expression and represented as mean ± SEM. *: 
p<0.05, ***: p<0.001, unpaired Student's t test, CMP and GMP versus LSK.  
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5. CC-Chemokine receptor expression is up-regulated in Ackr2-/-hematopoietic 
progenitors 
 
The analysis of HPCs revealed that there was an inverse correlation between the 
expression of ACKR2 and CCR2 on those cells. Thus, we investigated the expression of 
CCR2 in Ackr2-/- HPCs. RT-PCR analysis showed that LSK, CMP and GMP isolated from 
Ackr2-/- mice expressed higher levels of CCR2 compared to the same cells isolated from 
WT mice (Figure 5A). FACS analysis confirmed an increased expression of CCR2 in 
Ackr2-/- LSK, CMP and GMP cells and revealed that this up-regulation was restricted to 
monocyte and neutrophil progenitors, indeed there was no difference in the expression of 
CCR2 between WT and Ackr2-/- erythrocyte progenitors (Linneg, Sca-1-, cKit+, CD34-, FcγR-
, MEP) (Figure 5B). Furthermore, we evaluated the expression of CCR1 and CCR5 in 
HPCs by RT-PCR analysis and, in line with the data observed for CCR2, LSK, CMP and 
GMP isolated from Ackr2-/- mice expressed higher levels of CCR1 and CCR5 compared to 
WT (Figures 5C and 5D). These results indicate that ACKR2 in HPCs controls the 
expression of inflammatory chemokine receptors known to be involved in myeloid cell 
release from BM.  
Moreover, given the relevance of CXCR4 in controlling cell mobilization from BM, we 
evaluated CXCR4 expression, and we did not find differences in mRNA and protein levels 
of CXCR4 between WT and Ackr2-/- HPCs (Figures 5E and 5F). Thus, suggesting that the 
increased mobilization seen in Ackr2-/- mice is not due to CXCR4 down-regulation in 
HPCs. 
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Figure 5: Increased expression of CC chemokine receptors in hematopoietic 
progenitors of Ackr2-/- mice. A: Analysis of CCR2 expression by RT-PCR in LSK, CMP, 
and GMP cells sorted from BM of WT and Ackr2-/- mice. B: Analysis of CCR2 expression 
by FACS on LSK, CMP, GMP, and MEP of WT and Ackr2-/- mice. C, D, E: Analysis of 
CCR1 (C), CCR5 (D), and CXCR4 (E) expression by RT-PCR in LSK, CMP, and GMP 
cells sorted from BM of WT and Ackr2-/- mice. F: Analysis of CXCR4 expression by FACS 
on LSK, CMP, GMP, and MEP (F) of WT and Ackr2-/- mice. Data were relative to β-actin 
expression (A, C, D, E), expressed as mean fluorescence intensity (MFI) ratio on isotype 
(B), or as MFI (F). Results were represented as mean ± SEM. **: p<0.01, ***: p<0.001, 
unpaired Student's t test, Ackr2-/- versus WT.  
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6. Ackr2-/- LSK cells display increased differentiation rate 
 
Since the expression of chemokine receptors is regulated during maturation, we 
investigated whether the increased expression of CC chemokine receptors in Ackr2-/- HPCs 
was associated with altered maturation of LSK. To this aim we sorted LSK cells from BM 
WT and Ackr2-/-, we cultured them and we analyzed the expression of differentiation 
markers after 3 and 6 days of culture. We found that Ackr2-/- LSK cells cultured in vitro 
had increased expression of the myeloid differentiation markers CD11b and Ly6C after 3 
days of culture (Figures 6A and 6C), and increased expression of CD11b, Ly6G, and Ly6C 
(Figures 6A, 6B and 6C) after 6 days of culture, as compared to WT. These data confirm 
that the receptors CCR1, CCR2 and CCR5 do not mediate any myelosuppressive effect, 
whereas the absence of ACKR2 results in increased differentiation of LSK cells. 
 
            A                     B                                          C       
     
 
 
Figure 6: Increased differentiation rate of Ackr2-/- LSK cells. A, B, C: FACS analysis of 
CD11b (A), Ly6G (B), and Ly6C (C) expression on LSK sorted from BM of WT and 
Ackr2-/- mice after 3 and 6 days of culture. Data were expressed as mean fluorescence 
intensity (MFI), and represented as mean ± SEM. *: p<0.05, ***: p<0.001, unpaired 
Student's t test, Ackr2-/- versus WT.  
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7. ACKR2 overexpression in human promyelocytic leukemia cell line (HL-60) 
reduces CCR2 and CD11b expression  
 
In a second set of experiment, we took advantage of an in vitro system to assess the 
contribution of ACKR2 in regulating the maturation of HL-60. The latter is a 
promyelocytic cell; it expresses CCR2 and to lesser extent also ACKR2 (Figure 7A). Thus, 
in order to study ACKR2, we transfected HL-60, with either mock vector (Mock) or 
ACKR2 expressing vector (hACKR2). PCR analysis at 24 hours after cell transfection 
confirmed the expression of ACKR2 in transfected cells (Figure 7B). RT-PCR analysis 
revealed a significantly reduction of CCR2 and CD11b expression levels in HL-60 
overexpressing ACKR2 (Figure 7C). The expression level of CXCR4 was not affected 
(Figure 7C). Together, these results suggest that ACKR2 controls the expression of CCR2 
and the maturation of HPCs. 
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                                    A 
                                        
 
        B                                                                C                
                   
 
 
Figure 7: ACKR2 over-expression results in down-regulation of CCR2 and CD11b in 
HL-60 cells. A: Analysis of ACKR2 and CCR2 expression by RT-PCR in HL-60 cells. B: 
Analysis of ACKR2 expression in HL-60 transfected cells by PCR. C: Analysis of CCR2, 
CD11b, and CXCR4 expression by RT-PCR in HL-60 cells transfected either with mock 
or ACKR2 expressing vector. Data were relative to GAPDH expression, and expressed as 
percentage (A) or fold on mock (C). Results were represented as mean ± SEM. *: p<0.05, 
***: p<0.001, unpaired Student's t test, hACKR2 vs Mock. 
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8. Ackr2-/- and WT BM cells do not differ in the expression of transcriptional 
regulators of myelopoiesis 
 
Next, we assessed whether the change in chemokine receptor expression and the 
maturation seen in Ackr2-/- HPCs was due to the alteration of transcription factors 
regulating myelopoiesis. To answer this question we analyzed the transcript levels of 
STAT3 that induces granulopoiesis, CEBPβ and RORC1, which regulate emergency 
granulopoiesis, PU.1 and IRF8, which support monocyte differentiation, and finally Bcl3 
and Socs3 that negatively regulate myelopoieisis. As shown in Figure 8A, neither factor 
which positively or negatively regulates myelopoiesis was differentially expressed between 
WT and Ackr2-/- BM total cells, thus suggesting that none of those factors was responsible 
of enhanced LSK maturation in Ackr2-/- mice. 
 
 
                                            A 
                               
 
Figure 8: Expression of transcriptional regulators of myelopoiesis. A: Analysis of 
STAT3, CEBPβ, PU.1, IRF8, Bcl3, Socs3, and RORC1 expression by RT-PCR. Data were 
relative to GAPDH expression, and represented as mean ± SEM. 
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9. Neutrophil mobilization is required for metastases protection in Ackr2-/- mice 
 
Given the importance of myeloid cell development in cancer, we wanted to delineate the 
effect of increased CC chemokine receptor expression and maturation observed in Ackr2-/- 
LSK cells, in tumor challenged mice. To address this point we used an experimental model 
of lung metastasis by injecting B16F10 melanoma cells intravenously through the tail vein. 
As shown in Figure 9A, Ackr2-/- mice displayed a significant reduction in the number of 
metastatic foci, compared to WT. 
Next, we sought to understand whether myeloid cells were involved in Ackr2-/- mice 
protection from metastases. To this purpose, we evaluated the effect of monocyte or 
neutrophil depletion in tumor bearing mice. Thus, we injected B16F10 melanoma cells 
intravenously into the tail vein of WT and Ackr2-/- mice, and then we treated animals with 
an anti-CD115 monoclonal antibody to inhibit monocytes differentiation into macrophage 
or with an anti-Ly6G monoclonal antibody to deplete neutrophils. Although the inhibition 
of monocyte differentiation caused a significant reduction in the number of metastases in 
WT mice, it did not reverse the protection found in Ackr2-/- mice, whereas neutrophil 
depletion caused a reduction of metastases in WT mice and an increase in Ackr2-/- mice, 
which developed a number of lesions similar to untreated WT animals (Figure 9B).  
To further confirm that neutrophils were responsible for metastatic protection observed in 
Ackr2-/- mice, we performed an adoptive transfer experiments. We isolated neutrophils 
from WT and Ackr2-/- mice and 4 hours after intravenously injection of B16F10 melanoma 
cells into WT mice, we transferred WT or Ackr2-/- neutrophils. We found that Ackr2-/- 
neutrophils significantly reduced the number of lung metastases as compared to those 
animals injected with WT neutrophils (Figures 9C and 9D).  
Taken together, these results suggest that Ackr2 deficient neutrophils play a role in 
inhibiting the seeding of cancer cells into the lung, thus protecting Ackr2-/- mice from 
metastases. 
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             C                                              D 
 
 
Figure 9: Ackr2-/- neutrophils are required for metastases protection. A: Number of 
lung metastases in WT and Ackr2-/- mice 10 days after i.v. injection of 2X105 B16-F10 
cells. B: Number of lung metastases in WT and Ackr2-/- mice depleted for monocytes 
(αCD115) and neutrophils (αLy6G) 10 days after i.v. injection of 2X105 B16-F10 cells. 
Number of metastases was expressed as the ratio between the number of metastases of WT 
and Ackr2-/- mice treated with αCD115 or anti Ly6G and the number of metastases of WT 
and Ackr2-/- mice treated with IgG antibody. C: Number of lung metastases in WT mice 10 
days after i.v. injection of 2X105 B16-F10 cells and adoptive transfer of neutrophil isolated 
from BM WT or Ackr2-/-. D: Representative image of lungs 10 days after i.v. injection of 
2X105 B16-F10 cells. Data were represented as (mean ± SEM). *: p<0.05. 
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10.  Ackr2-/- neutrophils have an activated phenotype 
 
The decrease in the number of metastases in WT mice upon anti-CD115 and anti-Ly6G 
treatment was in agreement with the pro-tumoral role that these cells may have in tumor 
[289]. Hence, considering that neutrophils in cancer can be differently polarized, we next 
sought to determinate whether the opposite effect induced by the anti-Ly6G treatment in 
WT and Ackr2-/- animals, was due to a different phenotype of Ackr2-/- neutrophils. To this 
aim, we evaluated the activation state of neutrophils into the blood of WT and Ackr2-/- 
tumor-bearing mice. As shown in Figures 10A and 10B, neutrophils from Ackr2-/- animals 
expressed lower levels of CD62L (Figure 10A) and higher levels of ICAM-1 (Figure 10B), 
coherent with a more activated and mature phenotype. RT-PCR analysis revealed that 
genes, which are known to be differentially regulated in activated neutrophils, including 
TNFα, Alox5, VEGF-A, and Arg1, were equally expressed in BM neutrophils isolated 
from WT and Ackr2-/- mice (Figure 10C). Conversely, when we analyzed chemokine 
receptors expression, we found that CC chemokine receptors CCR1, CCR2 and CCR5 
were higher expressed in Ackr2-/- neutrophils, compared to WT, whereas no difference in 
the expression level of CXCR4 was observed (Figure 10D). To understand if ACKR2 was 
also controlling the expression of CC chemokine receptors in mature neutrophils, we 
sought whether WT neutrophils expressed ACKR2. We found that ACKR2 was very 
weakly expressed on WT neutrophils, and its level was much lower compared to LSK 
(Figure 10E). Taken together, these results suggest that ACKR2 deficiency in 
hematopoietic precursors, in addition to accelerate the maturation of myeloid cells, results 
in an increased expression of inflammatory chemokine receptors in mature neutrophils, 
which are more efficiently released from the BM and also exert an anti-metastatic function. 
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                A                                 B 
         
              C      D 
      
               E 
    
Figure 10: Ackr2-/- neutrophils display activated phenotype and increased expression 
of CC chemokine receptors. A, B: FACS analysis of CD62L expression on WT and 
Ackr2-/- neutrophils identified as CD45+ CD11b+ Ly6G+ (A), and frequency of ICAM+ 
neutrophils (B). C, D: Analysis of TNFα, Alox5, VEGF-A, and Arg1 (C), and CXCR4, 
CCR1, CCR2 and CCR5 (D) by RT-PCR. E: Analysis of ACKR2 expression on LSK, 
CMP, GMP and neutrophils isolated from BM WT. Data were relative to GAPDH (C, D), 
or β-actin (E) expression. Results were represented as mean ± SEM. *: p<0.05, ***: 
p<0.001, unpaired Student's t test, Ackr2-/- versus WT (A, B, C, D) and CMP, GMP and 
neutrophils versus LSK (E). 
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11.  AMD3100-treatment reduces the number of metastases in WT mice but does 
not affect metastases in Ackr2-/- mice  
 
Finally, we sought to determine whether increasing neutrophil mobilization would have 
resulted in improved metastatic protection in Ackr2-/- tumor bearing mice. To this aim we 
used AMD3100, the competitive inhibitor of CXCR4. AMD3100 treatment has been 
demonstrated to rapidly revert neutropenia in human patients; it acts by inhibiting the 
chemokine receptor CXCR4 thus disrupting the CXCL12/CXCR4 axis and promoting BM 
mobilization. We injected B16F10 melanoma cells intravenously through the tail vein of 
WT and Ackr2-/- mice and we treated animals with AMD3100. The treatment induced a 
significant reduction in the number of metastatic foci in WT animals compared to 
untreated WT mice, however Ackr2-/- mice developed a number of metastases similar to 
those observed in WT animals treated with AMD3100 (Figures 11A and 11B). Being 
CXCR4 highly expressed by tumor cells it is difficult to delineate its role in TAN biology. 
Moreover, CXCR4 expression by neutrophils has a pro-tumoral effect being CXCR4 
positive neutrophils pro-angiogenetic, as consequence CXCR4 inhibition may results in a 
reduction of neutrophil pro-tumoral activity both in WT and Ackr2-/- mice. However, these 
preliminary results suggest that CXCR4 inhibition can reduce metastatic seeding in WT 
mice, but is not able to enhance the metastatic protection in Ackr2-/- mice. 
 
                  A                                             B 
     
 
Figure 11: CXCR4 inhibition reduces the number of metastases in WT mice. A, B: 
Number of lung metastases (A) in WT mice either treated or untreated with AMD3100, 
and Ackr2-/- mice treated with AMD3100 10 days after i.v. injection of 2X105 B16-F10 
cells. Representative image of lungs (B) of WT mice treated or untreated with AMD3100, 
and Ackr2-/- treated with AMD3100 10 days after from i.v. injection of 2X105 B16-F10 
cells. Data were represented as (mean ± SEM). *: p<0.05, **: p<0.01, ***: p<0.001. 
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Discussion 
 
Chemokines and chemokine receptors are known to play a major role in the regulation of 
leukocyte recruitment in both homeostatic and inflammatory conditions, including cancer.  
Dampening the signal of almost all inflammatory CC chemokines and limiting their 
bioavailability in tissues, the atypical chemokine receptor ACKR2 represents an important 
mechanism of regulation of the chemokine system.  
Experimental approaches have unequivocally proven the regulatory function of ACKR2 in 
different model of inflammation, including infection, allergy, and cancer. The exacerbated 
inflammatory reactions observed in Ackr2-deficient mice have been attributed to the ability 
of ACKR2 to restrain the local inflammatory response, thus promoting the appropriate 
leukocyte recruitment and the successful migration of DCs to draining LNs. Moreover, by 
inhibiting the recruitment of inflammatory cells, ACKR2 limits Kaposi’s sarcoma growth 
and aggressiveness, controls TPA/DMBA and AOM/DSS-induced carcinogenesis, and in 
particular the inflammatory processes associated with tumor development. 
The general aim of this PhD thesis was to understand the role of ACKR2 in the context of 
myeloid cell BM mobilization and HPC differentiation, and to address the role of ACKR2 
in controlling myeloid cell effector functions. 
Most of CC chemokines, including CCL3, the ligand of ACKR2 have been identified as 
myelosuppressive and myeloprotective chemokines. Though none of the chemokine 
receptors has been already demonstrated to mediate this myelosuppressive effect, we found 
that Ackr2 deficiency in the hematopoietic compartment led to increased differentiation of 
HPCs, and enhanced monocyte and neutrophil mobilization in response to CCL3L1 
injection. Accordingly to the inhibitory activity of ACKR2 on HPC differentiation, 
ACKR2 was expressed in LSK cells and its expression was down-regulated in more 
differentiated CMP and GMP cells, in opposite way to the canonical chemokine receptor 
CCR2. Interestingly, the increased differentiation of Ackr2 deficient HPCs was associated 
to a higher expression of CC chemokine receptors CCR1, CCR2, and CCR5, which are 
important to sustain myeloid cell mobilization from BM, in those cells. 
The role of myeloid cells in cancer is still debated and controversial since they have been 
shown to play both pro-tumoral and anti-tumoral activity [258, 259, 290, 291]. However, 
taking advantage from a model of experimental metastasis we found that Ackr2-/- mice 
were protected from the development of lung metastases, and that the protection was 
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mediated by neutrophils. Indeed, depletion of neutrophils but not of monocytes reversed 
the protective phenotype observed in Ackr2-/- mice. Furthermore, the adoptive transfer of 
Ackr2-deficient but not WT neutrophils clearly reduced metastases in WT mice.  
Neutrophils are the most abundant leukocyte population, and essential effectors of innate 
immune response. Emerging evidences have indicated that neutrophils exert important 
functions in the tumor context, indeed they can have different phenotypic and functional 
properties, which depend either on their differentiation or activation state, and are able to 
alter tumor behaviour. N1 polarization is induced by IFN-β and inhibited by TGF-β, which 
lead neutrophils to assume a proinflammatory and cytotoxic phenotype towards tumor 
cells, whereas TGF-β stimulation and IFN-β inhibition promote N2 polarization that is 
related to an immunosuppressive and tumor-supporting growth phenotype [259]. N1 and 
N2 phenotypes can be distinguished by the expression of distinct molecules and 
chemokine receptors, hence in an effort to understand how neutrophils were mediating the 
metastatic protection in Ackr2 deficient mice, we analysed the phenotype of Ackr2-/- 
circulating neutrophils. 
The critical role for Ackr2 deficient neutrophils was further supported by the activated 
phenotype that these cells displayed. Indeed, we found that Ackr2-/- neutrophils expressed 
lower levels of CD62L/L-selectin and increased levels of ICAM-1, compared to WT. 
Moreover, neutrophils lacking ACKR2, as well as HPCs, showed increased expression of 
the chemokine receptors CCR1, CCR2 and CCR5 compared to WT mice. CD62L down-
regulation and ICAM-1 up-regulation are associated to an activated phenotype of 
neutrophils. Moreover, many studies have demonstrated that the up-regulation of CC 
chemokine receptors in neutrophils is functionally relevant since the stimulation with the 
cognate chemokines activates neutrophil effector functions such as respiratory burst 
activity and bacterial killing [252]. For example, despite the role of CCR2 in mediating the 
recruitment of monocytes that support tumor growth, evidences have demonstrate that 
CCR2 expression is crucial to induce BM mobilization of neutrophils with anti-metastatic 
activity, by producing ROS able to kill tumor cells in a CCR2-dependent manner [252]. In 
the future, we will, thus, deeper investigate this aspect by evaluating the possible 
differential production of ROS in response to CCR2 ligands between neutrophils WT and 
Ackr2-/-, and eventually the differential cytotoxic activity of WT and Ackr2-/- neutrophils 
towards tumor cells. 
The analysis of other genes differentially regulated in N1 and N2 neutrophils, such as 
TNFα, Alox5, VEGF-A, Arg1, and CXCR4 did not reveal any difference between WT and 
	   71	  
Ackr2-/- neutrophils. 
In an effort to improve the metastatic protection observed in Ackr2-/- mice, we treated WT 
and Ackr2-/- tumor bearing mice with AMD3100, the competitive inhibitor of CXCR4, 
which is known to induce a rapid mobilization of neutrophils from the BM. However, 
AMD3100 treatment did not induce difference in the development of metastases in WT 
and Ackr2-/- mice. Since CXCR4 is also express by B16F10 melanoma cells and by 
neutrophils with proangiogenic and pro-tumoral role, it is possible that Ackr2 deficiency 
was less prominent then CXCR4 inhibition, which was sufficient to reduced metastases 
both in WT and Ackr2-/- mice [261, 292]. 
The increased expression of CC chemokine receptors in HPCs and neutrophils of Ackr2-/-
deficient mice was clarified by using the promyelocytic cell line HL-60, and demonstrating 
that ACKR2 exerted a negative regulation on CC chemokine receptors expression and cell 
differentiation. Indeed, the overexpression of ACKR2 in HL-60 resulted in decreased 
transcript levels of CCR2 and CD11b. Since ACKR2 is weakly expressed in neutrophils, it 
is unlikely that ACKR2 is inhibiting the expression of CC chemokine receptors in those 
cells in WT mice. However, it is possible that the differential ontogenesis of WT and 
Ackr2-/- neutrophils influenced their chemokine receptor expression pattern and also their 
effector function. 
Even though ACKR2 overexpression in HL-60 proved the regulatory function exerted by 
ACKR2, the signaling pathway potentially involved is still unknown. In our laboratory it 
was demonstrated that the scavenger activity of ACKR2 is associated to a β-arrestin1-
dependent G protein-independent pathway which is functionally relevant for ACKR2 
internalization and recycling to the cell membrane [102]. Thus, we hypothesize that 
ACKR2 by activating the β-arrestin dependent signaling, also controls the expression of 
CC chemokine receptors by negatively regulating pathways involved in HPC 
differentiation and chemokine receptor expression. For example, the G-CSF pathway is 
important for HPC differentiation into neutrophils, and, in various myeloid cell lines, G-
CSF has been demonstrated to be able to induce CCR2 expression [193, 222]. Thus, it 
would be interesting to test whether the β-arrestin dependent signaling of ACKR2 leads to 
the inhibition of the G-CSF signaling, and negatively controls HPC proliferation and 
CCR2 expression, which is relevant for neutrophil mobilization and antimetastatic activity. 
In our set of experiment, we cultured LSK cells in presence of IL-6, IL-3, and SCF, which 
are important for LSK differentiation [190-192]. Whether the β-arrestin dependent 
signaling of ACKR2 is also inhibiting the signaling pathway of those molecules, and if 
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Ackr2-/- mice express different level of the receptors for IL-6, IL-3 and SDF-1 also remains 
to be investigated. 
Preliminary data regarding the analysis of STAT3, CEBPβ, PU.1, IRF8, Bcl3, Socs3, and 
RORC1 in BM total cells did not reveal any difference in the expression of these 
transcription factors between WT and Ackr2-/- mice. Therefore, in future, we will enrich 
LSK population in effort to find out whether analysing only the population where ACKR2 
is more expressed, we can appreciate differences in the expression of those transcription 
factors, involved in myelopoiesis, between WT and Ackr2-/-.  
In summary, our data indicate that ACKR2, through a pathway still undetermined, 
negatively regulates the expression of CC chemokine receptors in HPCs, inhibits their 
differentiation and, as consequence, the mobilization of myeloid cells. We thus provide 
another mechanism by which ACKR2 controls inflammation; however, we also found that 
ACKR2 by negatively regulating myeloid cell mobilization from the BM restrains the 
potential protective role that neutrophils may play in tumor context. 
By proving that besides its well-known chemokine scavenging activity and its regulatory 
functions on inflammation, ACKR2 restrict neutrophils anti-metastatic potential, we thus 
infer that ACKR2 inhibition might be a new strategy to target tumor microenvironment 
and to induce neutrophil polarization through a N1 anti-tumoral phenotype. 
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